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Abstract 
 
The emergence and proliferation of Gram-negative bacteria expressing -lactamases is a 
significant threat to human health. -Lactamases are enzymes that degrade the -lactam 
antibiotics (e.g., penicillins, cephalosporins, monobactams, and carbapenems) that we use to treat 
a diverse range of bacterial infections. Specifically, -lactamases catalyze a hydrolysis reaction 
where the -lactam ring common to all -lactam antibiotics and responsible for their 
antibacterial activity, is opened, leaving an inactive drug. There are two groups of -lactamases: 
serine enzymes that use an active site serine residue for -lactam hydrolysis and metalloenzymes 
that use either one or two zinc ions for catalysis. Serine enzymes are divided into three classes 
(A, C, and D), while there is only one class of metalloenzymes, class B. Clavulanic acid, 
sulbactam, and tazobactam are -lactam-based BLIs that demonstrate activity against class A 
and C -lactamases; however, they have no activity against the class A KPC and MBLs, NDM 
and VIM. Avibactam and vaborbactam are novel BLIs approved in the last two years that have 
activity against serine carbapenemases (e.g., KPC), but do not inhibit MBLs. The overall goals 
of this project were to use X-ray crystallography to study the catalytic mechanism of serine -
lactamases with -lactam antibiotics and to understand the mechanisms behind the broad-
spectrum inhibition of class A -lactamases by avibactam and vaborbactam. This project also set 
out to find novel inhibitors using molecular docking and FBDD that would simultaneously 
inactivate serine -lactamases and MBLs commonly expressed in Gram-negative pathogenic 
bacteria.  
 x 
 
The first project involved examining the structural basis for the class A KPC-2 -
lactamase broad-spectrum of activity that includes cephalosporins and carbapenems. Three 
crystal structures were solved of KPC-2: (1) an apo-structure at 1.15 Å; (2) a complex structure 
with the hydrolyzed cephalosporin, cefotaxime at 1.45 Å; and (3) a complex structure with the 
hydrolyzed penem, faropenem at 1.40 Å. These complex structures show how alternative 
conformations of Ser70 and Lys73 play a role in the product release step. The large and shallow 
active site of KPC-2 can accommodate a wide variety of -lactams, including the bulky 
oxyimino side chain of cefotaxime and also permits the rotation of faropenem’s 6-1R-
hydroxyethyl group to promote carbapenem hydrolysis. Lastly, the complex structures highlight 
that the catalytic versatility of KPC-2 may expose a potential opportunity for drug discovery. 
The second project focused on understanding the stability of the BLI, avibactam, against 
hydrolysis by serine -lactamases. A 0.83 Å crystal structure of CTX-M-14 bound by avibactam 
revealed that binding of the inhibitor impedes a critical proton transfer between Glu166 and 
Lys73. This results in a neutral Glu166 and neutral Lys73. A neutral Glu166 is unable to serve as 
a general base to activate the catalytic water for the hydrolysis reaction. Overall, this structure 
suggests that avibactam can influence the protonation state of catalytic residues. 
The third project centered on vaborbactam, a cyclic boronic acid inhibitor of class A and 
C -lactamases, including the serine class A carbapenemase KPC-2. To characterize 
vaborbactam inhibition, binding kinetic experiments, MIC assays, and mutagenesis studies were 
performed. A crystal structure of the inhibitor bound to KPC-2 was solved to 1.25 Å. These data 
revealed that vaborbactam achieves nanomolar potency against KPC-2 due to its covalent and 
extensive non-covalent interactions with conserved active site residues. Also, a slow off-rate and 
 xi 
 
long drug-target residence time of vaborbactam with KPC-2 strongly correlates with in vitro and 
in vivo activity. 
The final project focused on discovering dual action inhibitors targeting serine 
carbapenemases and MBLs. Performing molecular docking against KPC-2 led to the 
identification of a compound with a phosphonate-based scaffold. Testing this compound using a 
nitrocefin assay confirmed that it had micromolar potency against KPC-2. SAR studies were 
performed on this scaffold, which led to a nanomolar inhibitor against KPC-2. Crystal structures 
of the inhibitors complexed with KPC-2 revealed interactions with active site residues such as 
Trp105, Ser130, Thr235, and Thr237, which are all important in ligand binding and catalysis. 
Interestingly, the phosphonate inhibitors that displayed activity against KPC-2, also displayed 
activity against the MBLs NDM-1 and VIM-2. Crystal structures of the inhibitors complexed 
with NDM-1 and VIM-2 showed that the phosphonate group displaces a catalytic hydroxide ion 
located between the two zinc ions in the active site. Additionally, the compounds form extensive 
hydrophobic interactions that contribute to their activity against NDM-1 and VIM-2. MIC assays 
were performed on select inhibitors against clinical isolates of Gram-negative bacteria 
expressing KPC-2, NDM-1, and VIM-2. One phosphonate inhibitor was able to reduce the MIC 
of the carbapenem, imipenem 64-fold against a K. pneumoniae strain producing KPC-2. The 
same phosphonate inhibitor also reduced the MIC of imipenem 4-fold against an E. coli strain 
producing NDM-1. Unfortunately, no cell-based activity was observed for any of the 
phosphonate inhibitors when tested against a P. aeruginosa strain producing VIM-2. Ultimately, 
this project demonstrated the feasibility of developing cross-class BLIs using molecular docking, 
FBDD, and SAR studies.
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Chapter 1: 
 
Introduction 
 
 
1.1 Bacterial Antibiotic Resistance 
Bacteria are single-celled organisms that are ubiquitous throughout the earth, living in 
diverse environments ranging from hot springs and glaciers to the human body. The majority of 
bacteria are non-pathogenic; however, there are certain bacteria that have the ability to cause 
disease in humans [1, 2]. These pathogenic bacteria cause a variety of illnesses such as meningitis, 
pneumonia, gastroenteritis, and sepsis. Usually these illnesses are life-threatening, but the 
discovery of drugs known as antibiotics has dramatically decreased the rates of death. Antibiotics 
are drugs that selectively target bacteria and either inhibit or kill them by stopping a vital cellular 
process (Fig. 1.1) [3]. The modern antibiotic era began almost ninety years ago with the discovery 
of penicillin by Alexander Fleming. In 1928, Fleming serendipitously observed mold growing in 
dishes of Staphylococcus bacteria. Around this mold, no bacterial growth occurred. This led 
Fleming to hypothesize that the mold was secreting some substance that inhibited bacterial growth. 
Ultimately, the mold was identified as Penicillium rubens, and the name “penicillin” was used to 
describe the antibacterial substance [4, 5]. Several years later, large-scale production of penicillin 
was carried out, which provided the medical community a treatment option for a wide variety of 
bacterial infections [5]. Subsequently, many other classes of antibiotics such as aminoglycosides, 
sulfonamides, tetracyclines, macrolides, and quinolones were discovered and developed that added 
to our antibiotic arsenal [6, 7]. 
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Despite the successes surrounding the introduction of penicillin, there were some concerns 
about its use. In 1940, researchers reported that an Escherichia coli strain could inactivate 
penicillin by producing an enzyme known as penicillinase [8]. This observation was also 
documented in 1942 when hospitalized patients infected with strains of Staphylococcus aureus did 
not respond to penicillin treatment [9, 10]. Over the last fifty years, resistance to penicillin has 
skyrocketed, with an estimated 90-95% of S. aureus clinical isolates throughout the world 
demonstrating resistance to penicillin [11]. This resistance trend was also mirrored against other 
antibiotics. For example, aminoglycosides were discovered in 1946 and in the same year, 
resistance was already observed; tetracyclines were discovered in 1944, and by 1950, resistance 
was seen in the clinic [12].  
According to the Centers for Disease Control and Prevention (CDC), almost all bacterial 
infections are becoming increasingly resistant to the antibiotic therapy of choice [13]. In 2013, the 
CDC stated that the human race has entered the “post-antibiotic era”, in which infections typically 
cured by antibiotics are now becoming lethal [14]. The CDC estimates that each year in the United 
States, at least 2 million people contract a bacterial infection that is resistant to one or more 
antibiotics designed to treat that infection. Approximately 23,000 individuals die each year as a 
direct result of those antibiotic-resistant infections, though this number may be an underestimate 
because deaths attributed to HIV, cancer, or surgery, may in fact be due to an antibiotic-resistant 
bacterial infection [13]. Antibiotic resistance poses not only a health threat, but also an economic 
impact. In many cases, individuals diagnosed with an antibiotic-resistant infection will often 
require longer hospital stays, prolonged treatment, and more doctor visits than individuals with an 
infection that responds to antibiotic treatment. As a result, studies have estimated the economic 
impact of antibiotic resistance to be in the range of $6-60 billion annually [15, 16]. Therefore, 
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antibiotic resistance is quickly becoming an emerging global health epidemic and economic 
burden. 
 
1.2 Resistance to -Lactam Antibiotics 
Bacteria can utilize numerous mechanisms to become resistant to antibiotic treatment. The 
four main mechanisms of antibiotic resistance include: (1) enzymatic inactivation or modification 
of the drug, (2) target modification, (3) decreased drug penetration, and (4) bypass of pathways 
(Fig. 1.2) [17]. The first antibiotic resistance mechanism described was enzymatic inactivation of 
penicillin by penicillinases [18]. Penicillin belongs to a class of antibiotics known as -lactams, 
which also includes cephalosporins, monobactams, and carbapenems (Fig. 1.3) [19]. All -lactam 
antibiotics possess a four-membered -lactam ring at the core of their structure that is crucial to 
their antibacterial activity [20, 21]. -Lactam antibiotics are broad-spectrum antibiotics and work 
by interfering with the synthesis of the bacterial cell wall. The cell wall is vital to the survival of a 
bacterium for several reasons. Overall, the major functions of the bacterial cell wall are to help 
maintain the cell shape and protect the cell from osmotic changes that it may encounter in the 
environment [22-24]. The bacterial cell wall is composed of peptidoglycan, an organic polymer 
consisting of an interlocking network of the polysaccharides N-acetylglucosamine (NAG) and N-
acetylmuramic acid (NAM), cross-linked by short peptides [24]. The extensive cross-linking of 
peptidoglycan greatly contributes to the strength of the bacterial cell wall. This cross-linking 
process is catalyzed by a group of enzymes known as penicillin-binding protein (PBPs). PBPs are 
also known as DD-transpeptidases since they are responsible for forming the peptide cross bridge 
between chains of NAG and NAM [25, 26]. 
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Some bacteria can be classified according to the chemical and physical properties of their 
cell wall. This method is based on the Gram stain developed by Danish physician Hans Christian 
Gram in 1884. The Gram stain differentiates between Gram-positive and Gram-negative bacteria 
by staining these cells violet or pink. Gram-positive bacteria have a thick layer of peptidoglycan 
in their cell wall, and thus can retain the crystal violet dye when stained; whereas Gram-negative 
bacteria have a thinner peptidoglycan layer, which cannot retain the crystal violet dye when 
decolorized, and are subsequently counterstained pink [27]. The Gram stain is a very useful 
technique in identifying bacteria; however, not all bacteria can be Gram stained. For example, 
Mycobacterium species cannot be Gram stained due to the presence of mycolic acids in their cell 
walls, which prevent uptake of the dyes used [28]. 
The bacterial cell wall presents a promising target to antibiotics for a variety of reasons. 
Firstly, human cells lack cell walls, meaning that cell wall synthesis inhibitors will selectively 
target only bacterial cells [29]. Secondly, the cell wall is essential to the survival of a bacterium, 
and inhibiting its synthesis will ultimately result in cell death [22-24]. -Lactam antibiotics 
interfere with the cross-linking reaction that gives the cell wall its rigidity. -Lactam antibiotics 
resemble the natural substrate of PBPs, the D-Ala-D-Ala group found at the end of the pentapeptide 
precursors of peptidoglycan. This structurally similarity enables -lactam antibiotics to bind to 
PBPs and irreversibly acylate an active site serine residue [25]. 
  Although -lactam antibiotics have been a mainstay of treatment for a diverse range of 
bacterial infections, they are becoming less effective due to the emergence of antibiotic resistance. 
In general, there are three strategies that bacteria use to become resistant to -lactam antibiotics: 
(1) the synthesis of -lactam degrading enzymes known as -lactamases, (2) alteration of PBP 
targets, and (3) the active transport of -lactam molecules out of the cell via membrane-associated 
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proteins known as efflux pumps (Fig. 1.4) [25]. The most common mechanism of -lactam 
resistance among Gram-negative bacteria is the production of -lactamases that degrade the 
antibiotic before it can reach its PBP target [19, 30]. -Lactamases provide antibiotic resistance to 
bacteria by catalyzing the hydrolysis of the four-membered -lactam ring that is shared by all -
lactam antibiotics. Once the -lactam ring is hydrolyzed, the antibiotic is no longer effective [19]. 
What makes -lactamases even more worrisome is the fact that the genes encoding them are 
commonly located on mobile genetic elements, such as plasmids and transposons, which facilitates 
their spread among bacteria, further contributing to the problem of antibiotic resistance [31]. 
 
1.3 -Lactamase Classification 
-Lactamases can be classified using two different schemes. The first scheme classifies -
lactamases according to their substrate profiles and inhibition properties. This groups -lactamases 
into penicillinases, cephalosporinases, extended-spectrum -lactamases (ESBLs), and 
carbapenemases. Also taken into consideration is whether the -lactamases are inhibited by the -
lactamase inhibitors (BLIs) clavulanic acid, sulbactam, and tazobactam. Additionally, inhibition 
by the chelating agent ethylenediaminetetraacetic acid (EDTA) indicates the -lactamases are 
metalloenzymes [32]. The second and more commonly used classification scheme for -
lactamases is known as the Ambler classification, which groups -lactamases into four classes (A, 
B, C, and D) based upon their primary structure (Fig. 1.5) [32, 33]. Classes A, C, and D include 
enzymes that use an active site serine residue to carry out hydrolysis of -lactam substrates, 
whereas class B -lactamases (divided into subclasses B1, B2, and B3) are metalloenzymes that 
use one or two zinc ions to perform -lactam hydrolysis [32-34]. 
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The most abundant -lactamases belong to class A, comprising more than 550 enzymes. 
Among these enzymes, the most frequently encountered -lactamases include TEM, SHV, CTX-
M, and KPC [32, 35, 36]. Like PBPs, class A -lactamases form an acyl–enzyme complex with -
lactam antibiotics; however, unlike PBPs, class A -lactamases can carry out a deacylation 
reaction, liberating the enzyme and resulting in the release of a hydrolyzed -lactam product (Fig. 
1.6) [36-38]. There are key residues that are implicated in the acylation and deacylation reaction 
of class A -lactamase catalysis. It has been proposed that Glu166 serves as the general base in 
the acylation part of catalysis by deprotonating the catalytic Ser70 via a water molecule before 
Ser70 attacks the -lactam ring [39]. Glu166 is also involved in the deacylation reaction, where it 
serves as a base to activate a hydrolytic water molecule [40]. Mutagenesis of Glu166 impairs 
deacylation; however, Glu166 mutant enzymes are still able to form acyl–enzyme complexes [39]. 
This suggests that another active site residue, Lys73, which is located near other catalytic residues 
(Ser70, Ser130, and Glu166), can act as the general base during the acylation step. Ultrahigh 
resolution and neutron crystal structures of the Toho-1 E166A acyl–intermediate confirmed that 
Lys73 was neutral and can serve as the general base for the acylation reaction [41]. 
 Class C -lactamases are another major cause of -lactam resistance among bacterial 
pathogens. Members of the class C family include the clinically relevant -lactamases ADC, 
AmpC, CMY, and FOX [32, 42]. Overall, class C -lactamases behave very similarly to class A 
-lactamases in terms of catalysis. Class C -lactamases use an active site serine residue (Ser64) 
to attack the -lactam ring. Studies have suggested that two other residues play an important role 
in the activation of Ser64 for nucleophilic attack: Lys67 and Tyr150. Other studies have also 
proposed that the substrate may play a role in activation of Ser64 [43, 44]. For the deacylation 
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reaction, computational studies have suggested a Tyr150/Lys67 general base mechanism. Tyr150 
is largely protonated during the acyl–enzyme complex, in which prior to -lactam hydrolysis, 
transfers a proton to Lys67. This proton transfer allows Tyr150 to align towards and activate the 
catalytic water, while maintaining a hydrogen bond (HB) with Lys67. The catalytic water then 
carries out a nucleophilic attack on the carbonyl carbon of the acyl–enzyme complex, resulting in 
-lactam hydrolysis [45]. 
 Class D -lactamases, like classes A and C, are serine enzymes, but interestingly, the 
catalytic mechanism of class D -lactamases differs markedly [46, 47]. Class D -lactamases are 
commonly referred to as OXA enzymes, due to their ability to hydrolyze oxacillin, a penicillin 
derivative. Class D -lactamases include over 400 members, with clinically important enzymes 
such as OXA-24/40, OXA-48, and OXA-58 found in a variety of Gram-positive and Gram-
negative pathogens [48-51]. Class D -lactamases use an active site Ser70 to carry out nucleophilic 
attack on the -lactam ring; however, an unusual modification of Lys73 is observed in various 
crystal structures. Lys73 undergoes carbamylation, which has been demonstrated to be essential 
for both the enzyme acylation and deacylation steps of catalysis [46, 47, 51, 52]. This post-
translational modification of Lys73 is unique to class D -lactamases and has not been observed 
in any other class of -lactamase [52]. Another unique property of class D -lactamases is their 
susceptibility to inhibition by sodium chloride. Research has suggested that the presence of a Tyr 
residue at position 144 is correlated with inhibition by sodium chloride, as mutating Tyr144 to Phe 
alleviates sodium chloride inhibition [53, 54]. 
 Although class B -lactamases catalyze the same reaction as class A, C, and D -
lactamases, the mechanism by which they accomplish this does not involve an active site serine 
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residue or formation of a covalent intermediate [55]. Additionally, class B -lactamases have no 
sequence or structural similarity to class A, C, and D -lactamases [56]. Rather than using an active 
site serine residue, class B -lactamases are metalloenzymes that use zinc for activity. Class B -
lactamases or metallo--lactamases (MBLs), have as little as 25% sequence identity between some 
members; however, multiple crystal structures show that all MBLs have a common fold, known 
as an / sandwich fold, with the active site located between domains [57]. The active site of 
MBLs supports six residues that can coordinate either one or two zinc ions used in catalysis (Fig. 
1.7). MBLs are divided into three subclasses (B1, B2, and B3), which differ from one another 
based on amino acid sequence. B1 and B3 enzymes are maximally active when two zincs are 
bound in the active site. In B1 and B3 enzymes, the first zinc ion (called Zn1) is coordinated by 
three His residues. However, the residues coordinating the second zinc ion (called Zn2) differ 
between B1 and B3 enzymes. In B1 enzymes, Zn2 is coordinated by Asp, Cys, and His, whereas 
in B3 enzymes, Zn2 is coordinated by Asp, His, and His [57]. B2 enzymes, unlike B1 and B3 
enzymes, are most active with only one zinc in the active site, and binding of a second zinc ion is 
inhibitory. For B2 enzymes, the inhibitory Zn1 binding site is formed by Asn, His, and His, while 
the activating Zn2 binding site is formed by Asp, Cys, and His [58]. B1 and B3 enzymes have a 
broad-substrate profile that includes all -lactam antibiotics except aztreonam, while B2 enzymes 
selectively hydrolyze carbapenems [59].  
B1 enzymes are the most clinically relevant and researched MBLs, and include members 
such as NDM-1, IMP-1, and VIM-2 [55]. Catalysis of B1 enzymes begins with binding of the -
lactam substrate to the zinc metal center, with the carbonyl oxygen of the four-membered -lactam 
ring interacting with Zn1, and the carboxyl group on the five- or six-membered fused ring 
interacting with Zn2 (Fig. 1.8). A nucleophilic hydroxide ion stabilized and located between Zn1 
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and Zn2 is positioned for its attack on the carbonyl carbon of the -lactam ring. Attack of the -
lactam ring leads to the formation of a tetrahedral intermediate [57]. Ultimately, this tetrahedral 
intermediate is broken down; however, the mechanism by which this occurs is still debated. One 
proposed mechanism involves direct coordination of the substrate departing amine nitrogen to the 
zinc ion. Another hypothesis is that a metal-bound water molecule donates a proton to the amine 
nitrogen leaving group, leading to cleavage of the C-N bond [56]. 
 
1.4 Carbapenemases 
 Among all the -lactam antibiotics, carbapenems have the broadest spectrum of activity 
against Gram-positive and Gram-negative bacterial pathogens, and are often considered the last 
line of therapy against multi-drug resistant infections [60]. Carbapenems (e.g., imipenem, 
meropenem, doripenem, and ertapenem) are inherently stable against many different serine -
lactamases due to a unique chemical property (Fig. 1.9). -Lactams such as penicillins and 
cephalosporins have an acylamino substituent attached to the -lactam ring; however, 
carbapenems depart from this trend by having a hydroxyethyl side chain, which is key to their 
potency [60]. The hydroxyethyl group of carbapenems is attached in the trans-configuration, which 
differs from the cis-configuration found in the side chains of penicillins and cephalosporins (Fig. 
1.9) [61]. Studies have shown that the trans-hydroxyethyl group prevents the attack of the catalytic 
water on the acyl linkage due to electrostatic and steric hindrance, thereby trapping the -lactamase 
at the acyl–intermediate stage [60].  
Unfortunately, some -lactamases have evolved to include carbapenems in their substrate 
profile. These -lactamases commonly belong to classes A (e.g., KPC, GES, NMC-A, IMI, and 
SME), B (NDM, VIM, IMP, and SPM), and D (OXA-23, -24/40, -48, -51, -58, and -143) 
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[55,62,63]. Class C -lactamases are not typically classified as carbapenemases due to their weak 
hydrolytic activity against carbapenems; however, there are a few cases where carbapenemase 
activity has been observed in class C enzymes, most notably with CMY-10 [60, 64]. 
Of all the class A carbapenemases, the Klebsiella pneumoniae carbapenemase (KPC) is the 
most frequently encountered in clinic and causes the most health concern due to its location on 
mobile genetic elements such as plasmids and transposons. Although KPC is commonly found in 
K. pneumoniae, it is also found in other Gram-negative pathogens, especially those of the 
Enterobacteriaceae family [62, 65]. In fact, carbapenem-resistant Enterobacteriaceae (CRE) have 
been classified by the CDC as “an important emerging threat to public health” [66]. There are 23 
variants of KPC (KPC-2 to KPC-24), with KPC-2 being the most prevalent variant [67, 68]. 
Compared with noncarbapenemases (e.g., CTX-M, SHV, TEM), the active site of KPC-2 is larger 
and shallower, allowing for the accommodation of a wide variety of -lactams, even those with 
“bulky” side chains. This property enables KPC-2 to hydrolyze penicillins, cephalosporins, 
monobactams, carbapenems, and even the -lactam derived BLIs [69]. 
Carbapenem-hydrolyzing class D -lactamases (CHDLs) are a clinical problem due to their 
ability to compromise the use of carbapenem antibiotics. Most CHDLs are found in isolates of 
Acinetobacter baumannii; however, some CHDLs are found in K. pneumoniae and, to a lesser 
extent, other members of the Enterobacteriaceae family [63]. OXA-48 is one of the main CHDLs 
isolated around the world, and is commonly found in Mediterranean countries, Western Europe, 
and Africa [70]. OXA-48 has the highest catalytic efficiency for imipenem out of all the known 
class D -lactamases. This observation is reflected in OXA-48-producing K. pneumoniae strains 
exhibiting multi-drug resistance patterns, especially towards carbapenems [71]. Further 
 11 
 
complicating matters, OXA-48 is poorly inhibited by clavulanic acid, sulbactam, and tazobactam 
[70]. 
All MBLs can hydrolyze carbapenems and are not inhibited by the classical serine BLIs. 
The B1 enzymes NDM and VIM are commonly produced by CRE and Pseudomonas aeruginosa, 
two of the biggest threats to clinical therapies [55]. To date, 16 variants of NDM have been 
identified, with the major worldwide variant being NDM-1, and 46 variants of VIM have been 
discovered, with the most frequent variant being VIM-2 [55, 67, 72]. Interestingly, all MBLs are 
unable to hydrolyze the monobactam, aztreonam, which would be an effective therapy against 
bacteria solely producing MBLs; however, MBL-producing bacteria commonly produce serine -
lactamases as well, which can hydrolyze aztreonam. Therefore, aztreonam alone is usually not a 
reliable treatment option for MBL-producing bacteria [59, 73]. 
 
1.5 Clinically Approved BLIs 
 A tremendous amount of research has been carried out to discover BLIs that would 
hopefully restore the efficacy of the -lactam antibiotics. The first breakthrough occurred during 
the mid-1970s via a natural product screen that identified a compound produced by Streptomyces 
clavuligerus [74]. This compound was named clavulanic acid and possessed a structure similar to 
penicillin, including the -lactam ring. Clavulanic acid is a potent inhibitor of many clinically 
important class A -lactamases, and acts synergistically with -lactams to kill -lactamase 
producing bacteria. Further research led to the identification of two more BLIs, sulbactam and 
tazobactam, that increased the spectrum of activity to include class C -lactamases (Fig. 1.10) [75]. 
However, there are a few drawbacks to clavulanic acid, sulbactam, and tazobactam, which include: 
(1) these inhibitors on their own possess no antibacterial activity [76], (2) the presence of a -
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lactam ring makes these inhibitors susceptible to -lactamase mediated-resistance, and (3) they 
have no activity against the serine carbapenemases (e.g., KPC-2 and OXA-48) and MBLs (e.g., 
NDM-1 and VIM-2) [77]. 
 To help address the shortcomings of clavulanic acid, sulbactam, and tazobactam, novel 
BLIs are necessary. The first of these novel inhibitors was avibactam, a synthetic 
diazabicyclooctane (DBO), non--lactam inhibitor (Fig. 1.10). Unlike the previous inhibitors, 
avibactam can inhibit class A (including KPC-2), class C, and some class D -lactamases through 
a covalent, reversible mechanism [75, 78]. In 2015, the Food and Drug Administration (FDA) 
approved the combination of the third-generation cephalosporin, ceftazidime, with avibactam 
(marketed as Avycaz), to treat certain multi-drug resistant bacterial infections [77-79]. 
Unfortunately, avibactam has no activity against MBLs and some mutations in KPC appear to 
confer resistance to ceftazidime/avibactam [80, 81]. Another novel BLI called vaborbactam 
(formerly RPX7009), is a cyclic boronic acid compound with potent activity against KPC-2 and 
other class A and C enzymes (Fig. 1.10) [75, 77, 82]. Boronic acid compounds have long been 
established as potent inhibitors of serine -lactamases due to their ability to form covalent adducts 
with the active site serine residue [83]. Similarly, vaborbactam forms a reversible, covalent bond 
with the active site serine residue [77]. In 2017, the FDA approved the combination of meropenem 
(a carbapenem) with vaborbactam, marketed as Vabomere, for adults with complicated urinary 
tract infections, including pyelonephritis caused by CRE [84]. However, like avibactam, 
vaborbactam has no activity against MBLs [77]. Therefore, additional research is required to find 
an inhibitor with dual serine -lactamase and MBL activity. 
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1.6 Fragment-Based Drug Discovery 
Discovering novel inhibitors against protein targets is a challenging and time-consuming 
endeavor. The drug discovery process can be generally summarized into four stages: (1) target 
identification and validation, (2) lead discovery, (3) lead optimization, and (4) clinical trials [85]. 
Stumbles can be had at any of these stages; however, the hardest part is usually the second stage 
of lead discovery [86]. The starting point for lead candidates includes natural products, high-
throughput screening (HTS) of large compound libraries, and fragment-based drug discovery 
(FBDD) [87]. HTS and FBDD are the most common methods used for lead identification, both 
having certain advantages and limitations. The HTS method began in the late 1980s due to a shift 
from phenotypic to target-based drug discovery [88]. In HTS, a large number of compounds (~ 
105 – 106) are screened to assess for biological activity against a target. This has led to the 
identification of drug-like and lead-like compounds with desirable pharmacological and biological 
activity. Although HTS uses a large compound library, it only samples a small fraction of the 
chemical space of small molecules. FBDD is a powerful tool that has recently emerged and has 
been crucial in the small-molecule drug design process. Fragments are low-molecular-weight (< 
300 Da) compounds that usually have low binding affinity for the target [89-91]. These fragments 
are then modified, grown, and linked together to create a lead compound with high affinity and 
selectivity (Fig. 1.11). Compared to HTS, FBDD has the advantage of sampling a much wider 
chemical space, thus producing a significantly higher hit rate [91]. 
 
1.7 Molecular Docking 
Molecular docking has become an increasingly important computational tool that is vital 
to drug discovery. The goal of molecular docking is to predict the ligand binding mode to a protein 
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structure. Many variables play a role in the prediction of ligand-protein interactions, which include 
the flexibility of the ligand and target, electrostatic interactions, van der Waals interactions, 
formation of HBs, and presence of water molecules [92, 93]. The sum of these interactions is 
determined by a scoring function, which estimates binding affinities between the ligand and target 
(Fig. 1.11) [94]. Numerous molecular docking programs have been developed for both academic 
and commercial use that utilize different algorithms for ligand docking. Some of these programs 
include AutoDock [95], DOCK [96], Glide [97], and SwissDock [98]. 
 
1.8 X-ray Crystallography 
X-ray crystallography is a powerful technique that allows researchers to analyze the three-
dimensional structure of macromolecules such as proteins. X-ray crystallography is a multifaceted 
technique involving large scale expression of the protein of interest, purifying the protein, and 
setting up multiple crystallization trials in order to find suitable crystals for X-ray diffraction. 
Ultimately, solved protein structures are deposited into the Protein Data Bank (PDB), which 
currently contains over 100,000 protein structures solved using X-ray crystallography (Fig. 1.12) 
[99]. X-ray crystallography is an indispensable technique in FBDD and lead optimization. 
Analyzing the three-dimensional structure of a protein target bound by a ligand provides valuable 
insights into the interactions that drive binding affinity, as well as highlighting the potential areas 
for modification of the ligand in an effort to increase activity. This approach is known as structure-
based drug design (SBDD) since it combines the power of many techniques such as X-ray 
crystallography, nuclear magnetic resonance (NMR), medicinal chemistry, and FBDD to guide 
and assist drug development [100]. 
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1.9 Structure-Based Drug Design Targeting -Lactamases 
FBDD, molecular docking, and SBDD have all been used to discover novel inhibitors 
against serine -lactamases and MBLs [101]. One notable example of this success is against the 
class A -lactamase, CTX-M-9 [102]. For CTX-M-9, FBDD led to the discovery of a tetrazole-
based fragment inhibitor with a Ki of 21 M. A complex crystal structure of this compound in the 
active site of CTX-M-9 revealed two binding hot spots that could be exploited to increase affinity. 
The fragment was grown by adding substituents, and ultimately the affinity was improved more 
than 200-fold against CTX-M-9 (Fig. 1.13) [102]. 
 
1.10 Conclusions 
 Bacterial antibiotic resistance is quickly becoming a global health threat. A common 
mechanism of bacterial antibiotic resistance is the production of -lactamase enzymes that can 
deactivate the -lactam antibiotics (e.g., penicillins, cephalosporins, monobactams, and 
carbapenems). There are four classes of -lactamases that differ from one another based on their 
amino acid sequence and mechanism of action. Class A, C, and D -lactamases are enzymes that 
use an active site serine residue to perform -lactam hydrolysis, whereas class B -lactamases are 
metalloenzymes that use one or two zinc ions to catalyze the same reaction. One of the most 
alarming resistance trends is the emergence of carbapenemases that can deactivate virtually all -
lactam antibiotics. Carbapenemases such as KPC-2 (class A), NDM-1/VIM-2 (class B), and OXA-
48 (class D) have been reported in numerous Gram-negative pathogens. To address the issue of 
carbapenemases, inhibitors such as avibactam and vaborbactam were developed; however, these 
inhibitors fall short since they are active only against serine carbapenemases and not MBLs. This 
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dissertation will expand on the understanding of serine -lactamase catalysis and inhibition 
(Chapters 2, 3, and 4). Also presented will be the effort of finding a dual action serine 
carbapenemase and MBL inhibitor using molecular docking, FBDD, and structure-activity 
relationship (SAR) studies (Chapter 5). 
 
1.11 Note to Reader #1 
Figure 1.1 in this chapter was previously published by [12] Lewis, K. (2013). Platforms 
for antibiotic discovery. Nature Reviews Drug Discovery, 12(5), 371-387 and has been reproduced 
with permission (See Appendix 1). 
Figure 1.2 in this chapter was previously published by [12] Lewis, K. (2013). Platforms 
for antibiotic discovery. Nature Reviews Drug Discovery, 12(5), 371-387 and has been reproduced 
with permission (See Appendix 1). 
Figure 1.3 in this chapter was previously published by [57] Palzkill, T. (2012). Metallo--
lactamase structure and function. Annals of the New York Academy of Sciences, 1277(1), 91-104 
and has been reproduced with permission (See Appendix 1). 
Figure 1.4 in this chapter was previously published by [25] Wilke, M. S., Lovering, A. L., 
& Strynadka, N. C. (2005). -Lactam antibiotic resistance: A current structural perspective. 
Current Opinion in Microbiology, 8(5), 525-533 and has been reproduced with permission (See 
Appendix 1). 
Figure 1.6 in this chapter was previously published by [39] Vandavasi, V. G., Weiss, K. 
L., Cooper, J. B., Erskine, P. T., Tomanicek, S. J., Ostermann, A., Coates, L. (2016). Exploring 
the mechanism of -lactam ring protonation in the class A -lactamase acylation mechanism using 
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neutron and X-ray crystallography. Journal of Medicinal Chemistry, 59(1), 474-479 and has been 
reproduced with permission (See Appendix 1). 
Figure 1.7 in this chapter was previously published by [57] Palzkill, T. (2012). Metallo--
lactamase structure and function. Annals of the New York Academy of Sciences, 1277(1), 91-104 
and has been reproduced with permission (See Appendix 1). 
Figure 1.8 in this chapter was previously published by [57] Palzkill, T. (2012). Metallo--
lactamase structure and function. Annals of the New York Academy of Sciences, 1277(1), 91-104 
and has been reproduced with permission (See Appendix 1). 
Figure 1.9 in this chapter was previously published by [60] Papp-Wallace, K. M., 
Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011). Carbapenems: past, present, and future. 
Antimicrobial Agents and Chemotherapy, 55(11), 4943-4960 and has been reproduced with 
permission (See Appendix 1). 
Figure 1.12 in this chapter was previously published by [99] Shi, Y. (2014). A glimpse of 
structural biology through X-ray crystallography. Cell, 159(5), 995-1014 and has been reproduced 
with permission (See Appendix 1). 
Figure 1.13 in this chapter was previously published by [102] Nichols, D. A., Jaishankar, 
P., Larson, W., Smith, E., Liu, G., Beyrouthy, R., Chen, Y. (2012). Structure-based design of 
potent and ligand-efficient inhibitors of CTX-M class A -lactamase. Journal of Medicinal 
Chemistry, 55(5), 2163-2172 and has been reproduced with permission (See Appendix 1). 
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Figure 1.1. Antibiotic targets. Targets for antibiotics in bacteria include DNA 
synthesis, protein synthesis, cell wall synthesis, and folic acid metabolism. Adapted 
with permission from [12]. See Appendix 1. 
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Figure 1.2. Mechanisms of antibiotic resistance. The main mechanisms of antibiotic 
resistance include enzyme inactivation or modification, target modification, decreased 
drug penetration, increased drug efflux, and bypass of pathways. Adapted with 
permission from [12]. See Appendix 1. 
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Figure 1.3. Classes of ‐lactam antibiotics. (A) Core structure of penicillins. 
(B) Core structure of cephalosporins. (C) Core structure of monobactams. (D) 
Core structure of carbapenems. Different R‐groups distinguish various 
penicillin, cephalosporin, monobactam, and carbapenem derivatives. Adapted 
with permission from [57]. See Appendix 1. 
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Figure 1.4. Strategies for -lactam resistance. -Lactam resistance can be 
mediated by -lactamases, alterations in PBPs, and efflux pumps. Adapted with 
permission from [25]. See Appendix 1. 
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Figure 1.5. Ambler classification scheme of -lactamases. Schematic diagram of Ambler 
classification system. 
-Lactamases 
Serine Enzymes Metalloenzymes 
C A D B 
B1 B2 B3 
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Figure 1.6. Catalytic mechanism of class A -lactamases. Class A -lactamase catalysis proceeds 
through a two-step acylation/deacylation reaction that leads to -lactam hydrolysis. The acylation reaction 
initiates with the formation of a pre-covalent substrate complex (1). General base-catalyzed nucleophilic 
attack on the -lactam carbonyl by Ser70’s hydroxyl group proceeds through a tetrahedral intermediate 
(2) to a transiently stable acyl–enzyme adduct (3). In the deacylation phase, the acyl–enzyme adduct (3) 
undergoes general base-catalyzed attack by a hydrolytic water molecule to form a second tetrahedral 
intermediate (4), which collapses to a post-covalent product complex (5), from which the hydrolyzed -
lactam product is released. Adapted with permission from [39]. See Appendix 1. 
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Figure 1.7. Zinc coordinating residues of MBL subclasses. (A) Subclass B1, (B) subclass B2, 
and (C) subclass B3. Adapted with permission from [57]. See Appendix 1. 
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Figure 1.8. Catalytic mechanism of subclass B1 and B3 MBLs. The zinc ions are labeled and 
interactions are shown with dashed lines. (A) Cephalosporin substrate binds to the active site and 
interacts with both Zn1 and Zn2 via the carbonyl oxygen and carboxyl groups, respectively. The bound 
hydroxide is positioned to attack the carbonyl carbon of the substrate. (B) Anionic intermediate bound 
in the active site via stabilizing interactions provided by Zn2. Adapted with permission from [57]. See 
Appendix 1. 
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Figure 1.9. Comparison of carbapenems to penicillins and cephalosporins. (A) A 1--methyl (red) 
prevents breakdown from the renal enzyme dehydropeptidase I (DHP-I). (B) The pyrrolidine ring 
(red) increases stability and spectrum against multiple bacteria. (C) Penicillin, cephalosporin, and 
carbapenem chemical structures. Carbapenem has a five-membered ring, as does penicillin, but a 
carbon is located at position 1 instead of a sulfur. (D) All carbapenems have a hydroxyethyl group at 
C-6. (E) The R configuration of the hydroxyethyl increases the -lactam's potency. (F) The trans-
configuration of carbapenems at the C-5—C-6 bond increases their potency and stability against -
lactamases as compared to penicillins and cephalosporins, which have a cis-configuration. Adapted 
with permission from [60]. See Appendix 1. 
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Figure 1.10. Commonly used BLIs. -Lactam (clavulanic acid, sulbactam, and tazobactam) and 
non--lactam-based (avibactam and vaborbactam) BLIs. 
Clavulanic acid Sulbactam 
Avibactam Vaborbactam 
Tazobactam 
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Figure 1.11. General scheme for FBDD. In FBDD, a library of small 
molecules is placed into the binding site of a target using molecular 
docking. A scoring function ranks the molecules, and compounds are 
purchased or synthesized for biochemical testing. Low affinity 
inhibitors are selected and false positives are removed. The low 
affinity inhibitors are modified and linked together to create an 
inhibitor with high affinity for the target. 
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Figure 1.12. Growing number of protein structures deposited in the 
PDB. (A) The number of protein structures in the PDB are rapidly growing 
every year. As of 2017, there are over 100,000 protein structures found in 
the PDB. (B) Membrane proteins account for less than 5% of all deposited 
protein structures.  Adapted with permission from [99]. See Appendix 1. 
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Figure 1.13. Structure-based design of a CTX-M-9 BLI. Structure-based design was used in the 
development of a tetrazole-containing inhibitor of CTX-M-9, displaying nanomolar potency and cell-
based activity. Adapted with permission from [102]. See Appendix 1. 
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Chapter 2: 
 
Molecular Basis of Substrate Recognition and Product Release by the Klebsiella  
 
pneumoniae Carbapenemase (KPC-2) 
 
 
2.1 Overview 
 CRE are resistant to many β-lactam antibiotics, thanks in part to the production of the KPC-
2 class A -lactamase. Here, I present the first product complex crystal structures of KPC-2 with 
β-lactam antibiotics containing hydrolyzed cefotaxime (cephalosporin) and hydrolyzed faropenem 
(penem). These complex crystal structures provide experimental insights into the substrate 
recognition by KPC-2 and its unique broad-spectrum -lactamase activity. These structures also 
represent the first product complexes for a wild-type (WT) serine β-lactamase, which helped 
elucidate the product release mechanism of these enzymes. 
 
2.2 Introduction 
The KPC-2 class A β-lactamase poses a serious threat to nearly all β-lactam antibiotics [1]. 
KPC was first identified in North Carolina in 1996, and has since spread to many other countries 
[2]. Although initially identified in K. pneumoniae, KPC has also been discovered in other Gram-
negative bacterial pathogens, mainly belonging to the Enterobacteriaceae family [3]. The blaKPC 
gene encodes a 293 residue protein with 23 variants (KPC-2 through KPC-24) that differ from one 
another by only one or two amino acid changes [4]. KPC-2 is the most prevalent carbapenemase 
in the United States, and it has been termed the “versatile β-lactamase” due to its large and shallow 
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active site, permitting the efficient hydrolysis of virtually all β-lactam antibiotics [5]. However, 
the question still remains as to what specific interactions between β-lactams and the KPC-2 active 
site allow for such a broad substrate profile [6, 7]. The reaction catalyzed by class A β-lactamases 
proceeds through two steps: acylation and deacylation [3]. The nucleophilic attack of Ser70 on the 
substrate β-lactam ring results in a covalent acyl–enzyme complex. Subsequently, the catalytic 
water is activated by Glu166 and cleaves the acyl–enzyme linkage, leading to the formation of the 
hydrolyzed product. One common way to capture a β-lactam complex along the reaction pathway 
of class A β-lactamases is to mutate a key catalytic residue, such as Ser70 or Glu166, to 
accommodate the newly generated carboxylate group [8]. The complex structures presented herein 
represent the first product complexes using a WT serine β-lactamase with all native active site 
residues intact. This provides an accurate picture of the protein microenvironment that is 
responsible for catalysis, particularly during product release. 
 
2.3 Results and Discussion 
 I attempted to obtain complex crystal structures with a variety of β-lactams, including the 
cephalosporins ceftazidime, cefotaxime, cefoxitin, and nitrocefin; the penicillins ampicillin, 
cloxacillin, and benzylpenicillin; the carbapenems biapenem, imipenem, and meropenem; the 
penem faropenem; and the monobactam aztreonam. Ultimately, I was able to obtain two crystal 
structures of cefotaxime and faropenem as hydrolyzed products in the active site of KPC-2 (Fig. 
2.1). As discussed herein, the unique features of KPC-2, and the two substrates, may have 
contributed to the capture of these two complexes. 
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2.3.1 Product complex with cefotaxime 
 KPC-2 was crystallized in the space group P22121 with one copy of KPC-2 in the 
asymmetric unit (Table 2.1). KPC-2 crystals routinely diffracted to 1.15–1.5 Å resolution. The 
apo-structure is similar to that of previously determined KPC-2 models crystallized in different 
space groups (Fig. 2.2) [9, 10]. The product complex structure with cefotaxime was determined to 
1.45 Å resolution with final Rwork and Rfree values of 16.8% and 21.2%, respectively. The electron 
density for the product is well-defined in the active site as seen in the unbiased Fo–Fc map (Fig. 
2.3A). The occupancy value of the hydrolyzed product was refined to 0.86. There are some 
differences in the active site when comparing the cefotaxime complex structure to the apoenzyme, 
mainly with residues Ser70, Trp105, and Leu167 (Fig. 2.3B) because of interactions between the 
hydrolyzed product and the enzyme. The complex structure illustrates how the bulky oxyimino 
group of third-generation cephalosporins and the newly generated carboxylate group of the product 
are accommodated by the KPC-2 active site. It represents the first experimental structure of KPC-
2 in complex with a clinically used β-lactam antibiotic, and sheds new light on the extensive 
interactions between cefotaxime and the active site residues. The C4 carboxylate group resides in 
a subpocket formed by Thr235, Gly236, Thr237, and Ser130. This region is highly conserved in 
serine β-lactamases, and PBPs, as shown by previous crystallographic studies of these enzymes 
and their complexes [11, 12]. The six-membered dihydrothiazine group of the hydrolyzed product 
forms a pi–pi stacking interaction with Trp105, which has been demonstrated to be important in 
-lactam substrate recognition [13]. The interactions with the substrate also result in a single 
conformation of Trp105, which is observed to have two conformations in the apoenzyme (Fig. 
2.3B). Meanwhile, cefotaxime’s acylamide side chain is nestled in a pocket formed by Thr237, 
Cys238, Gly239, Leu167, and Asn170 (Fig. 2.3A). The aminothiazole moiety forms extensive 
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nonpolar interactions with Leu167, in addition to van der Waals contacts with Asn170, Cys238, 
and Gly239. In particular, compared with the apo-structure, the alkyl side chain of Leu167 moves 
closer to interact with the substrate (Fig. 2.3B). In comparison, the oxyimino group is largely 
solvent exposed and establishes relatively few interactions with the protein, mainly with 
Thr237C2 and Gly239C (Fig. 2.3A). 
As the first product complex with a WT serine β-lactamase, this KPC-2 structure also 
captures structural features not seen in previous β-lactamase complexes, particularly concerning 
the conformations of Ser70, Lys73, Ser130, and the substrate carbonyl group. In class A β-
lactamases, Ser70 carries out nucleophilic attack on the β-lactam ring of the substrate [14]. In the 
apoenzyme, Ser70 forms a HB with Lys73, which has been suggested as a potential base in the 
acylation step [15, 16]. In my structure, the presence of the newly generated C8 carboxylate group, 
a result of the catalytic water’s attack on the carbon atom of the acyl–enzyme carbonyl group, 
causes Ser70 to adopt a conformation that places its side chain hydroxyl group in the oxyanion 
hole formed by the backbone amide groups of Ser70 and Thr237, and previously occupied by the 
carbonyl oxygen of the acyl–enzyme intermediate (Fig. 2.3B, D). This conformational change 
abolishes the HB between Ser70 and Lys73 and establishes a new HB between Ser70 and the 
substrate ring nitrogen, an interaction not observed at any other stage of the reaction (Fig. 2.3B). 
Meanwhile, the side chain of Lys73 moves to form a HB with Ser130.  
Unlike most previous β-lactamase structures, Ser130 adopts two conformations (Fig. 2.3A) 
[17]. Conformation 1 maintains a weak HB with Lys73, is in close proximity to the ring nitrogen, 
and is the conformation usually observed in class A β-lactamases [18]; conformation 2 swings 
closer to Lys234 and the substrate C4 carboxylate group, establishing more favorable HBs with 
the latter two functional groups. Additionally, the amide nitrogen of the cefotaxime product forms 
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a weak HB with the backbone carbonyl group of Thr237 (Fig. 2.3A). In a previous CTX-M-14 
E166A complex structure with a ruthenocene-conjugated penicillin (PDB ID code: 4XXR) [19], 
Ser130 adopts conformation 1 and serves as a HB acceptor and donor in its interactions with the 
protonated ring nitrogen and a neutral Lys73, respectively (Fig. 2.3C). In my current structure, 
Lys73 appears to be protonated and is within HB distance (2.6–2.9 Å) to three HB acceptors, 
including Ser130O, Asn132O1, and the substrate C8 carboxylate group. In comparison, the 
distance between Lys73N and Ser130O of conformation 1 is 3.1 Å, suggesting a weak HB 
contact. Ser130O of conformation 1 is also too far away from the ring nitrogen (3.5 Å) for a HB. 
The weakened interactions between Ser130 and Lys73, or the substrate ring nitrogen, likely 
contribute to Ser130’s adoption of conformation 2, which highlights Ser130’s role in binding the 
substrate carboxylate group. Taken together, the alternative conformations of Ser70, Lys73, and 
Ser130 underscore the important noncatalytic roles these residues play in the product release 
process.  
Previous studies have suggested that steric clash and electrostatic repulsion caused by the 
newly generated C8 carboxylate group of cefotaxime is responsible for the expulsion of the 
hydrolyzed product from the active site [8, 20]. My structure supports this hypothesis and provides 
important new structural details on potential unfavorable interactions that lead to product 
expulsion. In my structure, possible clashes between the C8 carboxylate group and Ser70 are 
alleviated by Ser70’s adoption of an alternative, and likely high energy, conformation with a side 
chain χ1 angle of 10°, in comparison to the more favorable 60° in Ser70’s usual conformation. In 
the complex structure of the AmpC class C β-lactamase S64G mutant with hydrolyzed cephalothin 
(PDB ID code: 1KVL), the electrostatic repulsion between the C8 and C4 carboxylate groups 
caused the C4 carboxylate group to move out of the active site, resulting from the rotation of the 
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dihydrothiazine ring, and leading to an increase in distance between these two negatively charged 
groups [21]. In my structure, the C4 carboxylate group remains in the active site, albeit in a likely 
less stable state due to the electrostatic repulsion. Although the C8 carboxylate group can establish 
new interactions with Lys73, these contacts are accompanied by the loss of HBs between the 
substrate and the oxyanion hole, between Ser70 and Lys73, and for class A β-lactamases, by 
possible additional repulsion between the C8 carboxylate group and Glu166 (Fig. 2.3B). Another 
unique feature of the product complex is the lack of a HB between the substrate amide group with 
Asn132, even though the substrate amide group forms a HB with the backbone O atom of Thr237 
(Fig. 2.3A). The HB with Asn132 is present in nearly all complex structures of serine β-lactamases 
with β-lactams containing the amide group, including the aforementioned CTX-M-14 E166A 
product complex (PDB ID code: 4XXR) and a Toho-1 E166A/cefotaxime complex (PDB ID code: 
1IYO) structure (Fig. 2.3D) [8, 19, 22]. Instead, in this structure, the carbonyl oxygen is pushed 
out of the active site and exposed to solvent (Fig. 2.3C, D). The loss of the HB between the ligand 
amide group and Asn132 further suggests that the interactions between the product and the enzyme 
are less favorable compared with the Michaelis substrate complex, which may facilitate substrate 
turnover during catalysis. 
I observed an additional molecule of hydrolyzed cefotaxime near the active site, with a 
refined occupancy value of 0.72 (Fig. 2.4). This molecule did not make as many interactions in the 
active site as seen in the other hydrolyzed molecule. There is a HB between Lys270 and the C4 
carboxylate group of the second hydrolyzed product, as well as a HB between the aminothiazole 
group of the first hydrolyzed product and the C4 carboxylate of the second hydrolyzed product. I 
believe that the presence of this second hydrolyzed product is a crystal-packing artifact and does 
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not play a role in catalysis. Though interestingly, it may have partially stabilized the first 
hydrolyzed product inside the active site in the crystal. 
 
2.3.2 Product complex with faropenem 
Faropenem belongs to the penem class of β-lactam antibiotics (Fig. 2.1). Penems share the 
structural characteristics of both penicillins and cephalosporins [24]. Like carbapenems, penems 
have a hydroxyethyl group attached to the β-lactam ring in the trans-configuration that provides 
stability against many serine β-lactamases [5]. I captured a single hydrolyzed molecule of 
faropenem in the active site of KPC-2 (Fig. 2.5A). The complex structure with faropenem was 
solved to 1.40 Å resolution with final Rwork and Rfree values of 15.0% and 18.8%, respectively 
(Table 2.1). The occupancy value of the hydrolyzed product was refined to 0.84. Compared to the 
product complex with cefotaxime, the hydrolyzed faropenem induces similar conformations of 
Ser70 and Trp105, and makes many similar interactions in the active site (Fig. 2.5B). For instance, 
the C7 carboxylate group, which is analogous to the cefotaxime C8 carboxylate group, forms HBs 
with Ser130, Thr235, and Thr237; conformation 2 of Ser130 forms a HB with the C3 carboxylate 
group, which is analogous to the cefotaxime C4 carboxylate group (Fig. 2.5A). Unlike the 
cefotaxime complex, the ring nitrogen forms a HB with conformation 1 of Ser130, rather than 
Ser70, likely as a result of the smaller five-membered dihydrothiazole ring in faropenem, in 
comparison to the six-membered dihydrothiazine ring in cefotaxime. 
One important observation in this faropenem structure is the conformation of the 
hydroxyethyl side chain. The faropenem structure shows that the hydroxyethyl side chain has 
undergone rotation, abolishing its interaction with Asn132. Previous studies have shown that, in 
noncarbapenemases such as SED-1 (PDB ID code: 3BFF), the hydroxyethyl group of carbapenems 
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forms a HB with Asn132 and the catalytic water, consequently deactivating the catalytic water 
molecule and leaving these enzymes unable to hydrolyze the acyl–enzyme linkage [23]. However, 
in carbapenemases like KPC-2, the active site is enlarged, permitting rotation of the hydroxyethyl 
group, thus abolishing its interaction with Asn132 and allowing hydrolysis of carbapenem 
antibiotics (Fig. 2.5C) [23, 25-27]. Importantly, in the current structure, Leu167 is in favorable 
van der Waal contact with the methyl group of faropenem’s hydroxyethyl moiety, suggesting that 
Leu167 may play a catalytic role in inducing the rotation of this side chain group to facilitate 
carbapenem hydrolysis. Although position 167 is not well-conserved among class A β-lactamases, 
it appears that a leucine is conserved at this position in class A carbapenemases [11]. When 
comparing the cefotaxime and faropenem product complexes, movements are observed in Val103, 
the Pro104-Trp105 loop, and Leu167 (Fig. 2.5D). These movements are likely due to the different 
interactions between the faropenem tetrahydrofuran group and Trp105, and between the 
cefotaxime aminothiazole group and Leu167. In addition, because of the different chiralities of the 
C6/C7 atoms linked to the C7/C8 carboxylate group, the newly generated carboxylate group is 
positioned slightly differently between the two product complexes. Taken together, these findings 
highlight the flexibility of the KPC-2 active site for accommodating a variety of β-lactam side 
chains. 
 
2.3.3 Unique KPC-2 structural features for inhibitor discovery  
Despite extensive structural studies of numerous serine β-lactamases, my structures 
represent the only product complexes with a WT enzyme. All previous studies relied on mutations, 
such as S70G, to stabilize the interactions between the product and the enzyme active site [8]. The 
many unfavorable features of the enzyme–product contacts have made it difficult to capture such 
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complexes with WT enzymes, even for KPC-2, as demonstrated by the failures to obtain similar 
complexes using many other β-lactam antibiotics. The successes with my current two complexes 
may have been due to the particular side chains of these two substrates, and some unique properties 
of carbapenemases such as KPC-2. In comparison to other β-lactam compounds, the oxyimino side 
chain of cefotaxime and the tetrahydrofuran side group of faropenem enhance the interactions 
between the product and KPC-2, and avoids excessive bulkiness that may cause steric clashes with 
protein residues in a crystal-packing environment. More importantly, compared with narrow-
spectrum β-lactamases (e.g., TEM-1) and ESBLs (e.g., CTX-M-14), KPC-2 and other class A 
carbapenemases contain several key features and residues that result in an enlarged active site, 
including a Cys69–Cys238 disulfide bond, Leu167, Pro104, and Trp105. Movements of Ser70 and 
Asn170 are also observed in the KPC-2 structure. There is a larger distance between Ser70 and 
Asn170 in KPC-2 as compared to that in noncarbapenemases like TEM-1 and CTX-M-14, which 
may facilitate rotation of the hydroxyethyl group of carbapenems that endows them with stability 
against hydrolysis by many serine -lactamases [9]. Importantly, the KPC-2 active site also 
appears to be more hydrophobic, with larger nonpolar surfaces provided by Pro104, Trp105, 
Leu167, and Val240, in comparison to their counterparts Glu104, Tyr105, Pro167, and Asp240 in 
TEM-1 (Fig. 2.6A) and Asn104, Tyr105, Pro167, and Asp240 in CTX-M-14 (Fig. 2.6B). These 
features may allow KPC-2 to bind to a wide range of β-lactam substrates with a relatively open 
active site. They are mirrored by similar observations in MBLs that also harbor expanded active 
sites with a large number of hydrophobic residues [28]. Such features may enable carbapenemases 
to hydrolyze nearly all β-lactam antibiotics, while also exposing a weakness that can facilitate the 
engineering of high affinity inhibitors against these enzymes. 
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2.4 Conclusions 
 In this work, I present the first crystal structures of the KPC-2 class A β-lactamase in 
complex with two clinically used β-lactam antibiotics, cefotaxime and faropenem. The structures 
underscore the role of the enlarged and shallow active site in accommodating the bulky cefotaxime 
oxyimino side chain, the rotation of faropenem’s 6α-1R-hydroxyethyl group and, particularly, 
Leu167’s critical contribution in catalysis. These structures demonstrate how alternative 
conformations of Ser70 and Lys73 facilitate product release and capture unique substrate 
conformations at this important milestone of the reaction. Additionally, these structures highlight 
the increased druggability of the KPC-2 active site, which provides an evolutionary advantage for 
the enzyme’s catalytic versatility, but also an opportunity for drug discovery. 
 
2.5 Materials and Methods 
 
2.5.1 Cloning, expression, and purification of KPC-2 
 The KPC-2 gene sequence (residues 25-293) was cloned into the pET-GST vector between 
NdeI and BstBI restriction sites as an N-terminal His-tagged fusion protein. The construct was 
verified by DNA sequencing and transformed into BL21 (DE3) competent cells for protein 
expression. For His-tagged KPC-2, bacteria were grown overnight at 30 °C with shaking in 50 mL 
LB broth supplemented with 50 g/mL kanamycin. Two liters of LB broth supplemented with 50 
g/mL kanamycin, 200 mM sorbitol, and 5 mM betaine were each inoculated with 10 mL of 
overnight bacterial culture and grown at 37 °C until reaching an OD600=0.6-0.8. Protein expression 
was then initiated by the addition of 0.5 mM IPTG followed by growth for 16 hrs at 20 °C. Cells 
 49 
 
were pelleted by centrifugation and stored at -80 °C until further use. The His-tagged KPC-2 was 
purified by nickel affinity chromatography and gel filtration. Briefly, the cell pellets were thawed 
and re-suspended in 40 mL of buffer A (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM 
imidazole) with one complete protease inhibitor cocktail tablet (Roche) and disrupted by 
sonication, followed by centrifugation at 45,000 RPM to clarify the lysate. After centrifugation, 
the supernatant was filtered before loading onto a 5 mL HisTrap HP affinity column (GE 
Healthcare Life Sciences, USA) pre-equilibrated with buffer A. His-tagged KPC-2 was eluted by 
a linear imidazole gradient (20 mM to 500 mM). Fractions were analyzed by SDS-PAGE. 
Fractions containing His-tagged KPC-2 were pooled and loaded onto a Superdex75 16/60 gel 
filtration column (GE Healthcare Life Sciences) pre-equilibrated with 20 mM Tris-HCl pH 8.0, 
300 mM NaCl. Protein concentration was determined by absorbance at 280 nm using an extinction 
coefficient of 39,545. SDSPAGE analysis indicated that the eluted protein was more than 95% 
pure. The protein containing fractions were pooled and concentrated to 10-20 mg/mL. The protein 
was aliquoted and then flash frozen in liquid nitrogen, and stored at -80 °C. 
 
2.5.2 Crystallization and soaking experiments 
 Crystals of His-tagged KPC-2 were grown at 20 °C using hanging-drop vapor diffusion. 
Protein solutions (10-20 mg/ml) in 20 mM Tris-HCl pH 8.0, 300 mM NaCl were mixed 1:2 (v/v) 
with a reservoir solution containing 2 M ammonium sulfate and 5% (v/v) ethanol. Droplets (1.5 
L) were microseeded with 0.5 L of diluted seed stock. Crystals typically began to form within 
two weeks. To obtain the ligand bound structures, KPC-2 crystals were soaked in a solution 
containing 1.44 M sodium citrate and 30 mM cefotaxime/faropenem for 30 minutes. The soaked 
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crystals were cryo-protected in a solution containing 1.15 M sodium citrate, 20% (v/v) glycerol 
and flash-frozen in liquid nitrogen. 
2.5.3 Data collection and structure determinations 
 Data for the KPC-2 complex structures were collected using beamlines 22-ID-D and 23-
ID-D at the Advanced Photon Source (APS), Argonne, Illinois. Diffraction data were indexed and 
integrated with iMosflm [29] and scaled with SCALA from the CCP4 suite [30]. Phasing was 
performed using molecular replacement with the program Phaser [31], with the truncated KPC-2 
structure (PDB ID code: 3C5A). Structure refinement was performed using phenix.refine [32] and 
model building in WinCoot [33]. The unbiased Fo-Fc electron density maps were generated prior 
to refinement with compound. The program eLBOW [34] in Phenix was used to obtain geometry 
restraint information. The final model qualities were assessed using MolProbity [35]. Figures were 
generated in PyMOL 1.3 (Schrödinger) [36] in which structural alignments were generated using 
pairwise scores. LigPlot+ v.1.4.5 was used to generate ligand-protein interactions [37]. 
 
2.6 Note to Reader #1 
Portions of this chapter have been reproduced from Pemberton, O. A., Zhang, X., & Chen, 
Y. (2017). Molecular basis of substrate recognition and product release by the Klebsiella 
pneumoniae carbapenemase (KPC-2). Journal of Medicinal Chemistry, 60(8), 3525-3530 with 
permission of the 2017 American Chemical Society (see Appendix 1). 
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Figure 2.1. Chemical structures of intact and hydrolyzed cephalosporin and penem -lactam 
antibiotics. Structures of cephalosporins (cephalothin, cefotaxime), carbapenem (meropenem), and 
penem (faropenem) β-lactam antibiotics. 
 52 
 
 
  
Figure 2.2. Superimposition of apo KPC-2 structures. Green (PDB ID code: 3C5A), 
cyan (PDB ID code: 2OV5), purple (PDB ID code: 3DW0), current apo-structure (yellow). 
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Figure 2.3. KPC-2 cefotaxime product complex. The protein and ligand of 
the complex are shown in white and yellow, respectively. HBs are shown as 
black dashed lines. (A) Unbiased Fo–Fc electron density map (gray) of 
hydrolyzed cefotaxime contoured to 2σ. (B) Superimposition of KPC-2 product 
complex onto apoprotein (green) with details showing the interactions 
involving Ser70, Lys73, the cefotaxime ring nitrogen, and the newly formed 
C8 carboxylate group. PyMOL alignment RMSD = 0.153 Å over 272 residues. 
(C) Superimposition of KPC-2 product complex and CTX-M-14 E166A 
penilloate product complex with a ruthenocene-conjugated penicillin (green, 
with residues unique to CTX-M-14 E166A labeled in green) in stereo view. 
The ruthenium atom is shown as a gray sphere. PyMOL alignment RMSD = 
0.617 Å over 272 residues. (D) Superimposition of KPC-2 product complex 
with Toho-1 E166A acyl–enzyme complex with cefotaxime (green, with 
residues unique to Toho-1 E166A labeled in green). PyMOL alignment RMSD 
= 0.602 Å over 264 residues. 
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Figure 2.4. Two molecules of hydrolyzed cefotaxime in the KPC-2 active site. Hydrolyzed 
cefotaxime 1 and 2 (yellow) are shown in the active site of KPC-2. The unbiased Fo-Fc electron density 
map (gray) is contoured at 2 σ. HBs are shown as black dashed lines. The refined occupancy values 
of cefotaxime 1 and 2 are 0.86 and 0.72, respectively. 
T235 T237 
C238 
S130 
K73 
K270 
1 
2 
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Figure 2.5. KPC-2 faropenem product complex. The protein and ligand of 
the faropenem product complex are shown in white and yellow, respectively. 
HBs are shown as black dashed lines. (A) The unbiased Fo–Fc electron density 
map (gray) of hydrolyzed faropenem contoured at 2σ. (B) Superimposition of 
KPC-2 faropenem complex onto apoprotein (green) with details showing the 
interactions involving Ser70, Lys73, and the newly formed faropenem C7 
carboxylate group. PyMOL alignment RMSD = 0.141 Å over 270 residues. (C) 
Superimposition of KPC-2 product complex with SED-1 faropenem acyl–
enzyme (green) in stereo view. The deacylation water (red sphere) from SED-1 
is shown making interactions with Glu166 and the hydroxyethyl group of 
faropenem. PyMOL alignment RMSD = 0.555 Å over 262 residues. (D) 
Superimposition of faropenem/cefotaxime product complexes, showing the 
movement of the Pro104-Trp105 loop and alternative conformations for 
Val103 and Leu167 (KPC-2/faropenem: white/yellow; KPC-2/cefotaxime: 
green). PyMOL alignment RMSD = 0.101 Å over 270 residues. 
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Figure 2.6. Comparison of KPC-2 active site with the narrow-spectrum β-
lactamase TEM-1 and the ESBL CTX-M-14. (A) KPC-2 complexed with 
cefotaxime superimposed onto TEM-1 (KPC-2: white, TEM-1: green, 
cefotaxime: yellow). (B) KPC-2 complexed with faropenem superimposed 
onto CTX-M-14 (KPC-2: white, CTX-M-14: green, faropenem: yellow). 
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Figure 2.7. Molecular interactions of hydrolyzed cefotaxime and faropenem in the active site of KPC-2 from 
LigPlot+. (A) Hydrolyzed cefotaxime and (B) hydrolyzed faropenem. 
A B 
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*Statistics for the highest-resolution shell are shown in parentheses 
Table 2.1. X-ray data collection and refinement statistics for KPC-2 apo and hydrolyzed products 
Structure Apo KPC-2 KPC-2 with Hydrolyzed 
Cefotaxime 
KPC-2 with Hydrolyzed 
Faropenem 
Data Collection  
  
    
Space group P22121 P22121 P22121 
Cell dimensions    
a, b, c (Å) 55.80, 60.20, 78.62 56.93, 58.78, 76.84 57.14, 59.13, 77.38 
 (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 45.50-1.15 (1.21-1.15) 45.74-1.45 (1.53-1.45) 46.98-1.40 (1.48-1.40) 
No. of unique reflections 93,824 (12,888) 45,653 (6,335) 52,337 (7,543) 
Rmerge (%) 3.073 (36.2) 12.7 (68.4) 9.5 (88.8) 
I/σ(I) 11.0 (2.0) 9.1 (2.3) 9.9 (2.2) 
Completeness (%) 99.1 (94.4) 98.5 (95.6) 99.9 (100) 
Multiplicity 6.5 (3.3) 6.5 (5.3) 7.0 (6.6) 
 
   
Refinement    
 
   
Resolution (Å) 32.14-1.15 40.89-1.45 36.30-1.40 
Rwork (%) 12.2 (26.1) 16.8 (31.9) 15.0 (25.7) 
Rfree (%) 13.9 (26.9) 21.2 (34.5) 18.8 (27.5) 
No. atoms   
 
     Protein 2136 2090 2109 
     Ligand/Ion 26 60 26 
     Water   350 255 223 
B-factors (Å2)   
 
     protein 14.08 15.58 22.42 
     ligand/ion 28.32 22.02 37.11 
     water 31.96 30.91 36.78 
RMS deviations    
     Bond lengths (Å) 0.009 0.005 0.005 
     Bond angles (°) 1.08 0.85 0.81 
Ramachandran plot   
 
      favored (%) 98.88 98.88 98.87 
      allowed (%) 1.12 1.12 1.13 
      outliers (%) 0 0 0 
 PDB code 5UL8 5UJ3 5UJ4 
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Interactions of KPC-2 with 
hydrolyzed cefotaxime 
Distance (Å) 
Ser70 OG – Cefotaxime N23  2.95 
Lys73 NZ - Cefotaxime O21 2.58 
Ser130 OG – Cefotaxime O21 3.00 
Ser130 OG – Cefotaxime O27 2.98 
Thr235 OG1 - Cefotaxime O27 2.70 
Thr237 OG1 – Cefotaxime O26 2.55 
Thr237 O – Cefotaxime N07 3.21 
Interactions of KPC-2 with 
hydrolyzed faropenem 
Distance (Å) 
Ser70 OG – Faropenem O19 2.63 
Lys73 NZ – Faropenem O19 3.16 
Lys73 NZ – Faropenem O20 3.06 
Ser130 OG – Faropenem N06 3.10 
Ser130 OG – Faropenem O09 3.08 
Asn 132 ND2 – Faropenem O20 2.95 
Thr235 OG1 – Faropenem O09 2.64 
Thr237 OG1 – Faropenem O10 2.52 
Table 2.2. Hydrolyzed products hydrogen bond distances within 
KPC-2. HB distances between KPC-2 active site residues and 
hydrolyzed cefotaxime and faropenem products calculated from LigPlot+ 
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Chapter 3: 
 
Studying Proton Transfer in the Mechanism and Inhibition of Serine - 
 
Lactamase Acylation 
 
 
3.1 Overview 
 -Lactam antibiotics have long been considered a cornerstone of therapy for many life-
threatening bacterial infections. Unfortunately, the production of -lactam degrading enzymes 
known as -lactamases threatens their clinical use. A recent breakthrough in antibacterial drug 
discovery was the broad-spectrum BLI known as avibactam. Avibactam is a unique BLI because 
even though it can rapidly acylate a wide range of -lactamases, the covalent bond that it forms 
with the catalytic serine residue is particularly stable to hydrolysis. Previous crystallographic 
studies with class A -lactamases reveal that the catalytic water and Glu166, the general base for 
deacylation, appear to be intact in the complex and capable of attacking the covalent linkage with 
the inhibitor. Here I present a 0.83 Å resolution crystal structure of the class A -lactamase, 
CTX-M-14, bound to avibactam, showing a unique active site protonation state trapped by the 
inhibitor including a neutral Glu166 and a neutral Lys73. This structure suggests that the unique 
side chain of avibactam (i.e., hydroxylamine-O-sulfonate) stabilizes a neutral Lys73, preventing 
it from extracting a proton from Glu166. Subsequently, Glu166 is not able to serve as the general 
base to activate the catalytic water for the hydrolysis reaction. My structure illustrates how 
inhibitor binding can change the protonation states of catalytic residues. 
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3.2 Introduction 
-Lactamase production is the most common mechanism that Gram-negative bacteria use 
to destroy -lactam antibiotics before they reach their targets, the PBPs, which are responsible 
for cell wall synthesis [1]. -Lactamases are divided into two groups according to the mechanism 
that they use to catalyze -lactam hydrolysis. Serine enzymes use an active site serine residue in 
the covalent catalysis of the -lactam hydrolysis, whereas metalloenzymes use zinc ions for 
catalysis. There are three classes of serine enzymes (A, C, and D), while there is only one class 
of metalloenzymes, class B [2]. 
Class A -lactamases are the most prevalent class of -lactamase in hospital acquired 
infections and are usually found in a variety of Gram-negative bacteria such as members of the 
Enterobacteriaceae family [3, 4]. Class A -lactamases most commonly provide resistance to 
penicillins and first/second-generation cephalosporins. Fortunately, bacteria producing these 
enzymes generally remain susceptible to third-generation cephalosporins and carbapenems; 
however, this situation is quickly changing with the emergence of class A -lactamases 
displaying hydrolytic activity against third-generation cephalosporins and carbapenems [5, 6]. 
ESBLs can catalyze the hydrolysis of penicillins and first/second/third-generation 
cephalosporins. Currently, the class A CTX-M -lactamases are the most commonly identified 
ESBLs worldwide, with CTX-M-15 being the most frequent variant [2, 7]. Carbapenemases have 
an even broader spectrum of activity than ESBLs, and can hydrolyze virtually all -lactam 
antibiotics. The KPC class A -lactamase is the most common mechanism of carbapenem 
resistance in the United States. Of the many KPC variants, KPC-2 is the most frequently 
identified and characterized variant [2, 8, 9]. 
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 The emergence of -lactamases prompted the search for novel inhibitors that could 
reverse bacterial resistance against -lactam antibiotics. The first clinically available BLIs 
inhibitors were clavulanic acid, sulbactam, and tazobactam, which are potent inhibitors of class 
A (including CTX-M) and C -lactamases [10]. These inhibitors all contain a -lactam core 
structure, enabling them to bind to the active site of class A and C -lactamases and form a 
highly stable intermediate that permanently inactivates the enzyme. Specifically, clavulanic acid, 
sulbactam, and tazobactam are suicide inhibitors of serine -lactamases because they covalently 
bond to the catalytic serine residue and abolish enzymatic activity. However, these inhibitors can 
be hydrolyzed by the more versatile carbapenemases (e.g., KPC-2 and MBLs) and consequently 
have no activity against these enzymes [10, 11]. 
 Avibactam is a rationally designed BLI targeting serine -lactamases that includes 
ESBLs (CTX-M-15) and serine carbapenemases (KPC-2) in its spectrum of activity. Avibactam 
has some unique properties that differentiates it from clavulanic acid, sulbactam, and 
tazobactam: (1) avibactam does not contain a -lactam ring, but instead possesses a DBO 
structure that incorporates features of -lactams into its scaffold (Fig. 3.1); and (2) avibactam is a 
covalent, reversible inhibitor of serine -lactamases, which is a radical departure from the 
irreversible inhibition seen in the -lactam-based BLIs (Fig. 3.2) [10-12]. 
 To understand the mechanism by which avibactam possesses broad-spectrum of activity 
against class A serine -lactamases, a high-resolution X-ray crystal structure of avibactam bound 
to the CTX-M-15 class A -lactamase was solved [12]. This structure revealed that the catalytic 
serine (Ser70) of this enzyme carries out nucleophilic attack on the carbonyl of the five-
membered cyclic urea, resulting in opening of the avibactam ring and acylation of the enzyme 
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(Fig. 3.2) [12]. Acylation of CTX-M-15 can proceed through one of two pathways. The first 
pathway involves Glu166 activating Ser70 for nucleophilic attack via a water molecule. The 
second pathway proposes that Lys73 serves as the general base responsible for Ser70 activation. 
Mutagenesis of Glu166 to a Gln demonstrated a comparable avibactam acylation rate to WT, 
whereas mutating Lys73 to an Ala almost completely abolished avibactam acylation [13]. These 
data suggest that Lys73 is the general base during acylation and plays a direct role in activating 
Ser70 during avibactam acylation; however, there is still not a clear consensus as to which 
pathway predominates [13]. 
Ser130 is a residue that plays a critical role in avibactam acylation and subsequently 
deacylation. During acylation, Ser130 behaves as a general acid and donates a proton to the N6 
nitrogen of avibactam following ring opening [14]. The reversible nature of avibactam inhibition 
derives from its ability for recyclization (i.e., ring closure) after acylation (Fig. 3.2) [13, 15]. In 
order for avibactam recyclization to occur, the N6 nitrogen must be deprotonated. During 
deacylation, Ser130 now behaves as a general base, extracting a proton from the N6 nitrogen, 
which facilitates ring closure [13]. The intact avibactam molecule can then go on an acylate other 
-lactamases, or even the same -lactamase [15].  
 The complex that avibactam forms with serine -lactamases is very stable to hydrolysis. 
In fact, recyclization of avibactam is favored over hydrolysis [16, 17]. Key questions remain as 
to why the covalent bond avibactam forms with serine -lactamases is so stable against 
hydrolysis, despite the presences of a water molecule perfectly positioned to attack the bond [12, 
13]. Performing ultrahigh resolution X-ray crystallography on the CTX-M-14 class A -
lactamase, I attempt to answer this question by directly observing the protonation states of 
Lys73, Ser130, and Glu166, residues implicated in a proton transfer process. 
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3.3 Results and Discussion 
3.3.1 Crystal structure of avibactam bound to CTX-M-14 
The crystal structure of avibactam bound to CTX-M-14 was solved to 0.83 Å resolution. 
In the active site, electron density corresponding to avibactam was identified (Fig. 3.3). The 
electron density shows that there is a covalent linkage between avibactam and the catalytic 
Ser70. Besides the acyl–enzyme covalent bond, there are four other key interactions observed 
between the inhibitor and enzyme, which are the highly polar sulfate moiety, carboxamide group, 
C7 carbonyl group, and piperidine ring (Fig. 3.4). The sulfate moiety binds in a polar region of 
CTX-M-14, that commonly recognizes the carboxylate group on -lactam substrates [18-20]. 
The sulfate group has two conformations, with the dominant conformation establishing HBs with 
Thr235 and Ser237, and interacts via attractive charges with Lys234 and Arg276. The 
carboxamide group forms HBs with the sidechains of Asn104 and Asn132. The C7 carbonyl 
group of avibactam is positioned within the oxyanion hole formed by the backbone amides of 
Ser70 and Ser237. The piperidine ring forms a modest Van der Waals interaction with Tyr105. 
In addition to these interactions, Ser130 is within HB distance (2.90 Å) of the N6 nitrogen, 
which is hypothesized to play a role in the acylation and recyclization of avibactam as a general 
acid/base [14].  
  
3.3.2 Ultrahigh resolution reveals the protonation states of Lys73 and Glu166 
The 0.83 Å resolution crystal structure of CTX-M-14/avibactam enabled direct 
observations of the protonation state of two key catalytic residues, Lys73 and Glu166 (Fig. 3.5). 
The unbiased Fo-Fc map shows that side chain amine nitrogen (N) of Lys73 has two protons, 
indicating that it is neutral. The conformation of Lys73 is positioned to form a strong HB (2.8 Å) 
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with Ser130 HG, where the proton on the Ser130 side chain is clearly visible in the Fo-Fc 
electron density map. This observation is consistent with molecular dynamic (MD) simulations 
studying avibactam recyclization during which dynamic stabilities of the HB between Ser130 
and Lys73 were investigated [16]. These simulations showed that for 99% of the time, a HB is 
present between Lys73 N and Ser130 HG, with some snapshots showing an N ··· H distance as 
short as 1.5 Å, suggesting that a proton transfer from Ser130 to Lys73 is possible [16]. This 
proton transfer would coincide with Ser130 behaving as a general base to extract a proton from 
the N6 nitrogen, thereby promoting recyclization of avibactam.  
From the crystal structure, it appears that the protonation state of Glu166 is closely tied 
with that of Lys73. Analyzing the Fo-Fc map showed a protonated and neutral Glu166. In order 
for the catalytic water to become activated for nucleophilic attack on the covalent linkage, 
Glu166 must be able to transfer its proton to Lys73, to then act as a general base. However, this 
process is energetically unfavorable based on MD simulations [21]. Instead, the Lys73-Ser130 
dyad can serve as a better general base to activate the N6 nitrogen of avibactam for 
intramolecular nucleophilic attack on the carbamyl linkage to reform the N6-C7 bond, and 
generate the intact avibactam molecule (Fig. 3.2) [13, 16] 
 
3.4 Conclusions 
Together with previous high-resolution crystal structures of avibactam with class A -
lactamases, this new data allows us to track the transfer of a proton throughout the entire 
acylation process, and demonstrate the essential role of Lys73 in transferring the proton from 
Ser70 to Ser130 and ultimately to the N6 nitrogen of avibactam. Also revealed was that a 
protonated Glu166 is unable to transfer a proton to Lys73, and subsequently cannot act as the 
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general base to catalyze hydrolysis of the EI complex. In conjunction with computational 
analysis, this structure also sheds new light on the stability and reversibility of the avibactam 
acyl–enzyme complex, highlighting the effect of substrate functional groups in influencing the 
protonation states of catalytic residues and subsequently the progression of the reaction. 
 
3.5 Materials and Methods 
  
3.5.1 Expression and purification of CTX-M-14 
  The CTX-M-14 gene was cloned into a modified plasmid vector pET-9a. E.coli BL21 
(DE3) transformed with the plasmid pET-blaCTX-M-14 was cultured in LB broth containing 
kanamycin at 100 μg/mL at 37 °C for 5 h. Overexpression of the CTX-M-encoding gene was 
induced with 0.5 mM IPTG overnight at 20 °C. Cells were harvested by centrifugation (10,000 g 
for 10 min at 4 °C) and then disrupted by ultrasonic treatment (four times for 30 sec, each time at 
20 W). The extract was clarified by centrifugation at 48,000 g for 60 min at 4 °C. After addition 
of 2 μg of DNase I (Roche), the supernatant was dialyzed overnight against 20 mM MES–NaOH 
(pH 6.0). The purification was carried out by ion-exchange chromatography on a fast-flow CM 
column (Amersham Pharmacia Biotech) in 20 mM MES buffer (pH 6.0) and eluted with a linear 
0–0.15 M NaCl gradient. The enzyme was more than 95% homogeneous as judged by 
Coomassie blue staining after SDS-PAGE. The purified protein was dialyzed against 5 mM Tris–
HCl buffer (pH 7.0) and concentrated to 20 mg/mL for crystallization. 
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3.5.2 Crystallization and structure determination 
 CTX-M-14 was crystallized in 1.0 M potassium phosphate buffer (pH 8.3) from hanging 
drops at 20 °C. The final concentration of the protein in the drop ranged from 6.5 to 10 mg/mL. 
Avibactam complex crystals were obtained through soaking methods, with a compound 
concentration of 5.0 mM and soaking times varying from 3 h to 24 h. Crystals were cryo-
protected in 1.0 M potassium phosphate buffer (pH 8.3) and 30% sucrose (w/v) and flash frozen 
in liquid nitrogen. Diffraction was measured at 23-ID-B of GM/CA@APS at Advanced Photon 
Source (APS), Argonne, Illinois. Diffraction data were indexed, integrated, and scaled with 
HKL2000 [22]. The complex structure was refined with phenix.refine [23] from the PHENIX 
suite. Model rebuilding was performed using WinCoot [24]. Figures were prepared using 
PyMOL 1.3 (Schrödinger) [25] and Discovery Studio Visualizer [26]. 
 
3.6 Note to Reader #1 
 Figure 3.2 in this chapter was previously published by [12] Lahiri, S. D., Mangani, S., 
Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & Docquier, J. (2013). Structural 
insight into potent broad-spectrum inhibition with reversible recyclization mechanism: 
Avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -lactamases. 
Antimicrobial Agents and Chemotherapy, 57(6), 2496-2505. doi:10.1128/aac.02247-12 and has 
been reproduced with permission (See Appendix 1).  
 71 
 
  
4 
3 
2 
1 
6 7 
8 
5 
Figure 3.1. Chemical structure and numbering of atoms of avibactam. 
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Figure 3.2. General mechanism of avibactam inhibition against serine -lactamases. 
Adapted with permissions from [12]. See Appendix 1. 
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S70 
Figure 3.3. Crystal structure of avibactam bound to CTX-M-14. The Fo-Fc omit electron 
density map around avibactam is represented in blue and contoured at 2 . 
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Figure 3.4. Schematic diagram of CTX-M-14/avibactam interactions. Various interactions 
that avibactam forms with CTX-M-14 and avibactam are displayed in a schematic diagram 
generated by Discovery Studio Visualizer. 
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E166 
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Figure 3.5. Protonation states of active site residues in CTX-M-14/avibactam complex. The 
2Fo-Fc electron density map is represented in blue and contoured at 3 . The Fo-Fc electron 
density map is represented in red and contoured at 2 . Red sphere represents a water molecule. 
Hydrogen atoms can be observed on K73, S130, and E166, indicating a neutral K73 and E166. 
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Chapter 4: 
 
The Influence of Binding Kinetics on Inhibition of KPC-2 by Vaborbactam in  
 
Countering Bacterial Resistance 
 
 
4.1 Overview 
 KPC-2 hydrolyzes nearly all -lactam antibiotics, including carbapenems, and is 
responsible for antibiotic resistance in many pathogenic bacteria, particularly CRE. The recently 
approved avibactam has been used as a KPC-2 inhibitor in the clinic, yet resistance has already 
emerged. Here, I demonstrate that vaborbactam, a novel boronic-acid based BLI, behaves as a 
slow, tight-binding inhibitor and can effectively reverse bacterial resistance caused by KPC-2, 
including Ser130 mutants resistant to avibactam. In particular, vaborbactam displayed 
significantly higher cell-based activity against KPC-2 than CTX-M-15, an ESBL, even though it 
has similar binding affinities for both enzymes. Analysis of binding kinetics revealed a correlation 
between vaborbactam's cell-based activity against KPC-2, and a slower koff value in comparison 
to CTX-M-15. The molecular basis of this difference, as well as the roles of Ser130 in the 
inhibition mechanisms of vaborbactam versus avibactam, is illustrated by the first crystal complex 
structure of KPC-2 with vaborbactam, determined at 1.25 Å. My studies provide valuable insights 
into the use of vaborbactam in combating antibiotic resistance, and the importance of binding 
kinetics in novel antibiotic development. 
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4.2 Introduction 
 CRE are an emerging health threat due to their production of carbapenemases, which are a 
unique group of -lactamases that possess the ability to hydrolyze nearly all -lactam antibiotics 
[1]. CRE infections are associated with high rates of morbidity and mortality worldwide due to 
limited treatment options [2, 3]. One of the most common mechanisms of carbapenem resistance 
among CRE is the production of the KPC-2 class A -lactamase [4]. Class A -lactamases, like 
KPC-2, use a catalytic serine residue to mediate the opening of the -lactam ring, similar to class 
C and D -lactamases [5]. In contrast, the last remaining class B -lactamases rely on zinc ions 
for activity [6]. 
To address the growing problem of antibiotic resistance, numerous BLIs have been 
developed that when combined with a -lactam, are therapeutic in the treatment of multi-drug 
resistant bacterial infections [7]. However, some clinically available BLIs, such as clavulanic acid 
and tazobactam (Fig. 4.1), have poor activity against KPC-2 [8, 9]. In 2015, a potent non--lactam 
based BLI, known as avibactam (Fig. 4.1), was approved in combination with the third-generation 
cephalosporin, ceftazidime, to combat bacteria producing KPC-2, AmpC, and ESBLs [10-12]. 
Unfortunately, clinicians have observed cases of avibactam resistance due to porin mutations and 
plasmid-borne blaKPC-3 mutations [13-15]. These observations suggest that additional BLI 
discovery is vital against this rapidly changing resistance determinant. 
 Antibiotic development requires both the discovery of novel lead chemical scaffolds and a 
deep understanding of how these small molecules interact with their bacterial targets. Boronic 
acids have undergone extensive investigation as broad-spectrum serine BLIs due to formation of 
a stable covalent bond with the active site serine residue and the ability to readily diffuse through 
the outer membrane of Gram-negative bacteria, facilitating their uptake [16]. A boronic acid 
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transition state inhibitor (BATSI), known as S02030 (Fig. 4.1), was strategically designed to target 
a wide variety of serine -lactamases, including ADC-7, KPC-2, and SHV-1 with nanomolar 
potency [17]. Most recently, a cyclic boronic acid known as vaborbactam, has been shown to 
possess potent inhibitory activity against many class A and C -lactamases [18]. Particularly, 
vaborbactam can inhibit CTX-M, SHV, and CMY enzymes. Examining vaborbactam’s in vitro 
activity revealed that it can potentiate meropenem (a carbapenem) against clinical isolates of E. 
coli, Enterobacter cloacae, and K. pneumoniae expressing a wide range of serine -lactamases 
from classes A and C [19]. 
I have extended my studies of vaborbactam to the clinically important KPC-2. In particular, 
I am interested in how binding kinetics may influence the activity of vaborbactam. The importance 
of binding kinetics in drug efficacy has received increasing attention with numerous studies 
demonstrating that the residence time, i.e., the duration that the drug occupies the target binding 
site, is a superior indicator of a drug’s in vivo efficacy versus the inhibitor constant Ki [20, 21]. 
However, most of these studies focused on how the residence time can influence the 
pharmacokinetics of the drug inside animals or humans [22, 23]. It is largely unknown how binding 
kinetics can impact the activity of a drug on the cellular level, especially relative to their 
bactericidal effects. To characterize vaborbactam inhibition of KPC-2, I have performed binding 
kinetic experiments, MIC assays, mutagenesis studies, and solved the first crystal structure of 
vaborbactam bound to KPC-2. These results provide new insights into the unique properties of 
vaborbactam in combating carbapenem resistance caused by KPC-2, as well as the influence of 
binding kinetics on the cell-based activities of antibacterial compounds. 
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4.3 Results and Discussion 
 
4.3.1 Vaborbactam binding kinetics 
Previously published crystal structures of vaborbactam with CTX-M-15 and AmpC -
lactamases revealed the formation of a covalent bond between the catalytic serine residue of the 
enzyme and the boron atom of vaborbactam [18]. In agreement with these findings, a Lineweaver-
Burk plot of KPC-2 inhibition by vaborbactam demonstrated that it behaves as competitive 
inhibitor of this enzyme (Fig. S4.1). 
The number of BLI molecules that are needed to inactivate one molecule of a -lactamase, 
i.e., the stoichiometry or partition ratio, was also investigated. KPC-2 inhibition experiments using 
varying BLI concentrations revealed that one mole of vaborbactam was required to inhibit one 
mole of KPC-2 (Table 4.1). Avibactam demonstrated the same stoichiometry, while tazobactam 
and clavulanic acid required a much higher ratio for complete enzyme inhibition as KPC-2 can 
efficiently hydrolyze these suicide inhibitors [7]. Slow cleavage of avibactam by KPC-2 was 
reported previously [24], thus prompting me to investigate the stability of vaborbactam to this 
enzyme. Incubation of vaborbactam with KPC-2 for 18 h, with subsequent chromatographic 
analysis, revealed no change in the amount of vaborbactam (data not shown), indicating no effect 
of the enzyme on the vaborbactam chemical structure. 
When studied using a reporter substrate technique, typical “fast on – fast off”, or reversible, 
boronic BLIs (e.g., m-tolylboronic acid and 2-formylphenylboronic acid [25]) demonstrate a linear 
KPC-2 inactivation profile, indicating that equilibrium between the enzyme and inhibitor is 
quickly established (Fig. S4.2). My initial studies revealed a time-dependent decrease of Ki values 
when the incubation time of vaborbactam and KPC-2 was increased from the standard 10 min up 
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to 18 h (Fig. S4.3). That led me to hypothesize that, unlike other boronic BLIs, vaborbactam may 
exhibit progressive inactivation profiles typical for covalent, irreversible inhibitors [26]. Indeed, 
vaborbactam kinetic behavior was very similar to that demonstrated by tazobactam, with a slower 
onset of inhibition and non-linear inhibition curves indicating progressive KPC-2 inactivation (Fig. 
S4.4). This result suggests that vaborbactam’s interaction with KPC-2 follows a two-step kinetic 
mechanism with initial formation of a non-covalent EI complex, characterized by the binding 
constant K, which subsequently proceeds to a covalent interaction between the catalytic Ser70 of 
KPC-2 and boron atom of vaborbactam in the EI complex. The last step is characterized by the 
first-order rate constant k2. Independent determination of these values was impossible due to a 
linear relationship between kobs and vaborbactam concentration values up to the highest inhibitor 
concentration tested (data not shown). Similar kinetic behavior was previously reported for BLIs 
from various structural classes [27]. Therefore, the second-order rate constant k2/K for the onset 
of inhibition was determined. Vaborbactam and avibactam demonstrated comparable k2/K values 
of 7.3 x 103 and 1.3 x 104 M-1*s-1, respectively (Table 4.2). The recovery of KPC-2 activity after 
complete inhibition by vaborbactam was investigated by the jump dilution method [28]. This study 
demonstrated that vaborbactam inhibition of KPC-2 can be reversed (Fig. S4.5). However, the 
KPC-2 recovery rate was extremely slow with a koff of 0.000017 s
-1, indicating an enzyme 
residence time of 992 min (Table 4.2). For comparison, avibactam showed an approximately 10-
fold higher rate of activity recovery (koff = 0.00022 s
-1). Knowing the rate for the onset of inhibition 
and the koff rate allowed for calculation of the affinity, Kd, of the covalent complex (Table 4.2). 
The two inhibitors have similar inactivation efficiency against KPC-2, but at least a 10-fold 
difference in off-rates. As a consequence, vaborbactam appears to have a higher affinity for the 
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covalent complex than avibactam. Overall, vaborbactam functions as a slow, tight-binding 
inhibitor of KPC-2. 
Analyzing the inhibition of vaborbactam among -lactamases revealed some key 
differences in binding kinetics (Table 4.2). KPC-2 has a much slower koff (0.000017 s
-1), as 
compared to the ESBL, CTX-M-15 (0.00088 s-1). Ultimately, this leads to a much longer residence 
for KPC-2 (992 min) versus CTX-M-15 (19 min). 
 
4.3.2 Vaborbactam potentiation of aztreonam in KPC-2 and CTX-M-15 producing 
E. coli 
 As previously shown, vaborbactam has widely varying binding kinetics against KPC-2 and 
CTX-M-15 in terms of k2/K, koff, residence time, and Kd (Table 4.2). To observe how this would 
translate to in vitro activity, we performed MIC experiments with aztreonam (a monobactam) and 
varying concentrations of vaborbactam on KPC-2 and CTX-M-15 producing E. coli (Table 4.3). 
Interestingly, only 0.15 g/mL of vaborbactam was needed to reduce the MIC of aztreonam 64-
fold, whereas 10 g/mL of vaborbactam was needed to reduce the MIC of aztreonam 64-fold. 
 
4.3.3 Impact of S130G mutation on vaborbactam inhibition 
 Ser130 plays an important role in the catalytic mechanism of class A -lactamases, 
including KPC-2 [7], and mutations at this position significantly affect interactions with substrates 
and inhibitors, including the recently approved avibactam [24, 29]. The effect of the S130G 
substitution on vaborbactam potentiation of various antibiotics was studied in microbiological 
experiments with a strain of P. aeruginosa, PAM1154 [30] that lacks efflux pumps and carries 
plasmids expressing the WT and the mutant blaKPC-2. Consistent with earlier studies, KPC-2 
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S130G lost the ability to hydrolyze the majority of -lactam antibiotics [24, 29, 31]. P. aeruginosa 
producing the KPC-2 S130G variant demonstrated resistance to the penicillins, carbenicillin, and 
piperacillin, but not to other -lactams (Table S4.1). Subsequently, carbenicillin and piperacillin 
were chosen to study the concentration response to vaborbactam using a checkerboard 
methodology (Table 4.4). As previously reported, cells producing KPC-2 S130G were highly 
resistant to avibactam potentiation of penicillins [29, 31]; carbenicillin and piperacillin MICs 
against the KPC-2 WT producing strain were reduced 512- to 1024-fold by avibactam at 32 g/mL, 
and only 4- to 8-fold against the strain that produced KPC-2 S130G. Notably, the S130G 
substitution did not affect antibiotic potentiation by vaborbactam. 
 Studies with purified enzymes confirmed that the Ki value for avibactam inhibition of 
KPC-2 S130G was almost 6,000-fold higher than that for the WT KPC-2: 70 M vs 0.012 M. At 
the same time, the Ki of vaborbactam decreased from 0.034 M for the WT KPC-2 to 0.011 M 
for the S130G mutant. Detailed kinetic studies confirmed the significant effect of the S130G 
substitution on acylation efficiency of avibactam [24, 31, 32]; it was decreased almost 1,000-fold 
(Table 4.2). Conversely, vaborbactam inactivated the KPC-S130G variant with an almost 10-fold 
higher efficiency compared to its inactivation of the WT KPC-2. Another unexpected impact of 
S130G on vaborbactam kinetics was an over 200-fold increase in the rate of recovery of enzymatic 
activity (Table 4.2). Of note, due to an increase in the rate of onset of inhibition (k2/K), the Kd 
value remained in the nanomolar range, providing a possible explanation as to why the S130G 
mutation did not impact the antibiotic potentiation activity of vaborbactam. 
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4.3.4 Structure determination of vaborbactam with KPC-2 
 To understand how vaborbactam achieves potent inhibition of KPC-2 requires structural 
information to supplement our previously obtained structures of vaborbactam bound to CTX-M-
15 and AmpC [18]. Therefore, I co-crystallized KPC-2 with vaborbactam and solved the complex 
structure to 1.25 Å (Fig. 4.2, Table S4.2). KPC-2/vaborbactam co-crystals belong to the space 
group P22121, with one molecule in the asymmetric unit. The Fo-Fc map showed an unambiguous 
density in the KPC-2 active site corresponding to two closely related conformations of 
vaborbactam, differing from one another by a flip of the thiophene ring (Fig. 4.2A). Vaborbactam 
forms several HBs and extensive hydrophobic interactions with the enzyme (Fig. 4.2A). The NH 
of the amide group of vaborbactam donates a HB to the Thr237 backbone carbonyl, while the 
carbonyl of the same amide group of vaborbactam accepts a HB from the Asn132 sidechain amide 
NH2. The carboxylate group of vaborbactam is extensively coordinated by the hydroxyl side chains 
of Ser130, Thr235, and Thr237. The thiophene moiety of the inhibitor re-orients inward to make 
hydrophobic interactions with Trp105. The interactions that vaborbactam makes with KPC-2 
largely mimic the interactions that the -lactam antibiotics, cefotaxime and faropenem, form with 
KPC-2 [33]. 
Like most serine hydrolases, the KPC-2 active site contains an “oxyanion hole”, which is 
a small subpocket surrounded by several HB donor atoms that coordinate the carbonyl group 
oxygen of the substrate next to the scissile bond [34, 35]. In KPC-2, it is formed by the backbone 
amide NH groups of residues Ser70 and Thr237. A distinct feature of the vaborbactam complex is 
the mode of interaction with the oxyanion hole. Typically, substrates and inhibitors engage it with 
a single acceptor (oxygen atom or hydroxyl) [36-40]; vaborbactam on the other hand, inserts two 
oxygen atoms (exocyclic and endocyclic) into the oxyanion hole so that the Ser70 NH group is 
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interacting mostly with the exocyclic oxygen and the Thr237 NH group is interacting with 
endocyclic oxygen (Fig. 4.2A). 
Vaborbactam induces some conformational changes in the KPC-2 active site upon binding 
(Fig. 4.2B). In the apoenzyme (PDB ID code: 5UL8 [33]), Trp105 alternates between two 
conformations that flank opposite sides of the active site, whereas in the complex structure, Trp105 
adopts two conformations that are positioned to make hydrophobic contacts with the six-
membered ring and thiophene moiety of vaborbactam. One conformation of Trp105 is similar to a 
conformation observed in the apoenzyme, whereas the other conformation is unique to the 
particular complex, allowing the protein to establish more non-polar contacts with vaborbactam. 
In the apoenzyme, Ser130 also has two conformations. Conformation 1 forms a weak HB (3.5 Å) 
with Lys73 and is the conformation normally observed in class A -lactamases, whereas 
conformation 2 establishes a strong HB (2.7 Å) with Lys234 [33]. In the complex structure, Ser130 
adopts a single conformation, conformation 2, forming a HB with the vaborbactam carboxylate 
group. 
 
4.4 Conclusions 
 Bacterial antibiotic resistance to -lactam antibiotics is a significant health threat 
worldwide. Of notable health concern is the KPC-2 class A -lactamase due to its broad-substrate 
profile that includes penicillins, extended-spectrum cephalosporins, and carbapenems. My 
biochemical and structural analyses have provided important insights into the binding kinetics and 
molecular interactions underlying the clinical utility of vaborbactam, a unique cyclic boron-based 
BLI, in countering bacterial resistance caused by KPC-2 and its mutants. 
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Like other boronic acid inhibitors, vaborbactam acts as a covalent, yet reversible, ligand 
for -lactamases [41-43]. The apparent Ki values of these inhibitors are usually determined by 
steady-state kinetics using the hydrolysis reaction with reporter substrates such as nitrocefin. Due 
to the formation of a covalent bond, these inhibitors frequently have a slow koff, and the binding to 
the protein may not reach equilibrium during the biochemical assay. This is especially true for 
vaborbactam, whose residence time for KPC-2 is more than 10X longer than the duration of the 
experiment, usually in the range of 10-20 min. As a result, this can lead to an underestimate of the 
true Kd/Ki value. In my previous study using steady-state kinetics, vaborbactam displayed similar 
activities against both KPC-2 and CTX-M-15 [18]. My latest results provide a more accurate 
picture of the inhibition of these two enzymes by vaborbactam. The Kd value against KPC-2 is 
approximately 5X lower than previously reported. In comparison, the Kd for CTX-M-15 is similar 
to previous studies [18]. This is likely due to the shorter residence time of vaborbactam for CTX-
M-15, which allows the binding to reach equilibrium during the length of the assay. 
The longer residence time of vaborbactam for KPC-2 (992 min), in comparison to CTX-
M-15 (19 min), has translated into a significantly improved cell-based activity against the former 
enzyme than the latter. At 0.3 g/mL, vaborbactam decreased the MIC of aztreonam by >100-fold 
against KPC-2 expressing E. coli, but only 2-fold for CTX-M-15. Recent studies have highlighted 
the importance of residence time in the in vivo efficacy of many drugs, targeting both human and 
bacterial proteins [20-23]. For antibacterial targets, it has been suggested that the residence time 
should be at least comparable to the bacterial generation time (e.g., 20 min.) [7]. The residence 
time of vaborbactam for both KPC-2 and CTX-M-15 satisfies this criterion. The significant 
improvement in the cell-based activity suggests that a long residence time is important for the 
potency of antibacterial compounds, at least in the case of BLIs, even without considering the 
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pharmacokinetics inside the human body. At the same time, it raises the question as to why a 
residence time longer than the bacterial generation time can still be beneficial for antibiotic utility. 
For BLIs, this may be due to potential -lactamase activity even after bacterial cell death, as a 
result of the diffusion of both -lactamases and antibiotics. 
The high binding affinity and long residence time of vaborbactam for serine -lactamases 
is mostly derived from the covalent bond between the catalytic serine and the boron atom. 
However, the different binding kinetics of KPC-2 and CTX-M-15 illustrates the contribution of 
non-covalent interactions to the activity of vaborbactam. Vaborbactam was previously solved in 
the active site of CTX-M-15 to 1.50 Å resolution (PDB ID code: 4XUZ [18]). There are many 
similarities between vaborbactam in KPC-2 and CTX-M-15 (Fig. 4.3). Both the endocyclic and 
exocyclic oxygens of the vaborbactam ring enter and interact with the oxyanion hole formed by 
the backbone NH groups of Ser70 and Thr237 (in the case of KPC-2) and Ser70 and Ser237 (in 
the case of CTX-M-15). The exocyclic oxygen forms a HB with the NH group of Ser70, whereas 
the endocyclic oxygen HBs with the NH group of Thr237 in KPC-2 or Ser237 in CTX-M-15. 
Unlike CTX-M-15, KPC-2 and related carbapenemases possess a disulfide bond between 
the adjacent Cys69 and Cys238, that has been demonstrated to be important for activity [44, 45]. 
The presence of this disulfide bond appears to have a structural impact on the architecture of the 
KPC-2 active site as compared to the CTX-M-15 active site. The disulfide bond results in an 
outward shift of Gly239 and Val240, which contributes to the re-orientation of the thiophene 
moiety of vaborbactam due to potential steric clashing. Interestingly, the disulfide bond may also 
pre-adjust the backbone conformation around the oxyanion hole to allow insertion of the 
endocyclic and exocyclic oxygen atoms of vaborbactam. This difference is particularly evident 
when comparing CTX-M-15 structures (apo, PDB ID code: 4HBT [46]; vaborbactam, PDB ID 
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code: 4XUZ [18]; and avibactam, PDB ID code: 4HBU [46]). Indeed, vaborbactam binding to 
CTX-M-15 is accompanied by ~ 0.6 Å “bulging” of the backbone at Ser237 (Fig. 4.4A), enlarging 
the oxyanion hole (as compared to less than 0.2 Å movement for avibactam). On the other hand, 
virtually no backbone movement is seen around the oxyanion hole in our KPC-2/vaborbactam 
structure when compared with an apo structure of KPC-2 (PDB ID code: 5UL8 [33]); however, 
the structure of avibactam bound to KPC-2 (PDB ID code: 4ZBE [24]) does result in backbone 
shifts upstream, at Cys238 and especially Gly239 (Fig. 4.4B). This observation may in part explain 
the potency of vaborbactam against class A carbapenemases. 
One major difference between the KPC-2 and CTX-M-15 vaborbactam complexes is the 
conformation of the thiophene moiety. In CTX-M-15, the thiophene moiety assumes a linear 
conformation, whereas in KPC-2 the thiophene moiety bends inward to form hydrophobic 
interactions with Trp105 (Fig. 4.3). The presence of the large, non-polar tryptophan residue at 
position 105 in KPC-2 versus the smaller, and more polar tyrosine residue at position 105 in CTX-
M-15 likely contributes to this observation. In comparison to Trp105 in KPC-2, Tyr105 in CTX-
M-15 establishes fewer interactions with vaborbactam. This is due not only to the smaller size of 
Tyr105, but also due to its relative rigidity, which prevents it from moving closer to the ligand, 
like the second conformation of Trp105. In fact, this is a general trend observed in several CTX-
M and KPC-2 structures, which underscores the versatility of Trp105 in adapting to different 
ligands and contributing to the broad-spectrum activity of KPC-2 [33, 40, 47-49]. 
Overall, the more extensive non-covalent interactions between vaborbactam and KPC-2 
may explain its longer residence time compared with CTX-M-15; however, the increased 
complementarity may have been achieved with a significant entropic cost on the protein and the 
ligand, and led to the slower on-rate for KPC-2 (Table 4.2). On the protein side, the need for an 
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optimal Trp105 conformation can affect the kon rate, albeit on a smaller scale. This is reminiscent 
of previous studies showing protein conformational changes usually accompany long residence 
times [21, 50]. On the ligand side, vaborbactam adopts a very compact conformation in KPC-2, 
which affords little conformational freedom. In comparison, significant movement of the 
thiophene arm can be accommodated in the extended conformation in the CTX-M-15 active site. 
The strict conformational requirement for vaborbactam in the KPC-2 active site may be another 
factor contributing to the slower on-rate than CTX-M-15. 
Another interesting observation is that the S130G mutation seems to significantly increase 
the on-rate for KPC-2. I have recently found that Ser130 mutations in CTX-M-14 significantly 
increase the flexibility of the active site loop containing Ser130 (unpublished data). I hypothesize 
that similar effects in KPC-2 may lead to a more open active site, which may reduce the 
conformational restraints on vaborbactam. 
Although avibactam has been successfully used to target carbapenem-resistance caused by 
KPC-2, its clinical utility is threatened by emerging resistance mutations such as S130G [24, 31, 
32]. The Ser130 sidechain plays a significant role in the catalytic mechanism of class A -
lactamases, donating a proton to the nitrogen atom upon cleavage of the amide (lactam) bond [29]. 
Indeed, S130G mutant enzymes generally have much lower catalytic efficiency, with the 
remaining activity attributed to replacement of the Ser130 sidechain by a water molecule. 
Accordingly, avibactam and other inhibitors that depend on an Ser130-mediated acylation 
mechanism are strongly impacted by this mutation, resulting in substantial resistance [32]. Ser130 
mutations may be particularly detrimental to avibactam activity because they also affect the 
recyclization of the avibactam ring, which reverses the acylation reaction and allows the inhibitor 
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to be recycled [51]. In comparison, the boronate moiety of vaborbactam is not interacting with 
Ser130 and therefore, formation of the covalent adduct should not be affected by this residue. 
In conclusion, vaborbactam achieves nanomolar potency against KPC-2 due to its covalent 
and extensive non-covalent interactions with conserved active site residues. Its remarkable 
residence time on KPC-2 correlates with its favorable pharmacological properties. Ultimately, 
these in vitro findings corroborate the idea that a slow off-rate and long residence time translate to 
potent cell-based activity. Vaborbactam has shown promising results when combined with the 
carbapenem meropenem, and is marketed as Vabomere, which has been recently approved by the 
FDA. Vabomere provides a promising strategy for the treatment of serious Gram-negative 
infections caused by bacteria resistant to carbapenem antibiotics. 
 
4.5 Materials and Methods 
 
4.5.1 Generation of KPC-2 mutants 
Mutations in the KPC-2 gene cloned in either pUCP24 or pET28a plasmids were 
introduced using “QuikChange Lightning Site-Directed Mutagenesis Kit” (Agilent Technologies). 
The presence of desired mutations and the lack of unwanted ones were confirmed by DNA 
sequencing of the entire KPC-2 gene. 
 
4.5.2 Determination of MIC values and vaborbactam potentiation experiments 
 For microbiological studies, KPC-2 WT and its mutant genes were cloned in pUCP24 
shuttle vector. Resulting plasmids were transformed into P. aeruginosa PAM1154 strain. MIC 
values for various antibiotics were determined by the standard broth microdilution method using 
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cation adjusted Mueller-Hinton Broth [52]. Potentiation of antibiotic activity by vaborbactam in 
bacterial strains carrying WT and mutants KPC-2 genes were performed using standard checker 
board assay [53]. All microbiological studies were performed with 15 g/mL of gentamycin 
present in the media. 
 
4.5.3 Evaluation of KPC-2 mutant proteins expression level in PAM1154 strain 
 Bacterial cells carrying plasmids expressing KPC-2 mutants were grown in liquid media 
till OD600=0.7-0.9 and diluted to final OD600=0.5. 500 L of cell culture were spun down and 
resulting pellet was resuspended in 500 L of gel-loading buffer. 20 L of cell lysate was loaded 
on 8-16% SDS-PAGE. After gel transfer membrane was probed with custom produced rat anti-
KPC-2 antibodies and subsequently treated with secondary goat anti-rat HRP-conjugated 
antibodies. Anti-RNA polymerase -subunit monoclonal antibodies (Abcam, #ab12087) were 
used as loading control. 
 
4.5.4 Purification of KPC-2 WT and mutant proteins for biochemical studies 
 For protein expression, the full KPC-2 gene coding sequence with its Shine-Dalgarno box 
was cloned into the pET28a vector that produced a construct with periplasmic KPC-2 secretion 
and a 6xHis-tag on its C-terminus. The recombinant plasmids were transformed into E. coli 
BL21(DE3) pLysS cells. 2 mL of overnight culture was inoculated in 1 L of LB media with 50 
g/mL of kanamycin and 20 g/mL of chloramphenicol and grown at 37 oC with 300 RPM shaking 
until reaching an OD600=0.7-0.8. IPTG was added to 0.2 mM concentration and cells continued to 
grow for an additional 3 h. Cells were harvested by centrifugation and the cell pellet was 
resuspended in 40 mL of ice-cold 50 mM Tris-HCl pH 8.0, 500 mM sucrose, 1 mM EDTA, and 1 
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tablet of complete protease inhibitor tablet (Roche). Suspension was incubated on ice with six 
cycles of 15 sec vortexing and 5 min pause between them. Suspension was centrifuged for 30 min 
at 30,000 x g, supernatant was collected, sonicated for 30 sec to reduce viscosity and MgCl2 and 
imidazole were added to 2 mM and 5 mM concentrations, respectively. Lysate was loaded by 
gravity flow onto a 1 mL column with HisPur Cobalt Resin (Thermo Scientific) pre-equilibrated 
with 50 mM Na-phosphate pH 7.4, 300 mM NaCl, 5 mM imidazole buffer. Column was washed 
with 40 mL of the same buffer and consequently 6xHis-tag protein was eluted with 50 mM Na-
phosphate pH 7.4, 300 mM NaCl, 70 mM imidazole buffer. All wash and elution fractions were 
analyzed by 8-16% SDS-PAGE. Fractions containing target protein were pooled, concentrated, 
and dialyzed against 50 mM Na-phosphate pH 7.0. Purity of all proteins were at least 95% as 
determined by SDS-PAGE. Protein preparations were aliquoted and stored at -20 oC until further 
use. 
 
4.5.5 Determination of Km and kcat values for nitrocefin cleavage by KPC-2 and 
mutant proteins 
Purified protein was mixed with various concentrations of nitrocefin (NCF) in 50 mM Na-
phosphate pH 7.0, 0.1 mg/mL bovine serum albumin (BSA) (reaction buffer) and substrate 
cleavage was monitored at 490 nm every 10 sec for 10 min on SpectraMax plate reader at 37 oC. 
Initial rates of NCF cleavage were calculated and used to obtain Km and kcat values with Prism 
software (GraphPad). 
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4.5.6 Determination of Km and kcat Values for meropenem cleavage by KPC-2 and 
mutant proteins 
Purified protein was mixed with various concentrations of meropenem in reaction buffer 
and substrate cleavage was monitored at 294 nm every 30 sec for 30 min on SpectraMax plate 
reader at 37 oC. Initial rates of meropenem cleavage were calculated and used to obtain Km and 
kcat values with Prism software (GraphPad). 
 
4.5.7 Determination of vaborbactam Ki values for KPC-2 and mutant proteins using 
NCF as substrate 
Protein was mixed with various concentrations of inhibitors in reaction buffer and 
incubated for 10 min at 37 oC. 50 M NCF was added and substrate cleavage profiles were 
recorded at 490 nm every 10 sec for 10 min. Ki values were calculated by method of Waley, S.G 
[54]. 
 
4.5.8 Determination of vaborbactam Ki values for KPC-2 and mutant proteins using 
meropenem as substrate 
Protein was mixed with various concentrations of inhibitor in reaction buffer and incubated 
for 10 min at 37 oC. 100 M meropenem solution was added and substrate cleavage profiles were 
recorded at 294 nm every 30 sec for 30 min. Ki values were calculated as described in [54]. 
 
4.5.9 Stoichiometry of KPC-2 and mutant proteins inhibition 
Enzyme at 1 M in reaction buffer was mixed with BLI at molar ratios varying from 64 to 
0.0625. After 30 min incubation at 37 oC, reaction mixture was diluted 200-fold and enzyme 
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activity was measured with NCF as described above. Stoichiometry of inhibition was determined 
as a minimal BLI:enzyme ratio reducing enzyme activity to at least 10%. 
 
4.5.10 Determination of vaborbactam k2/K inactivation constant for WT KPC-2 and 
mutant proteins  
 Inactivation kinetic parameters were determined by the reporter substrate method [55] for 
slow, tight binding inhibitor kinetic scheme. 
          K      k2 
E + I ↔ EI ↔ EI* 
                   k-2 
Protein was quickly mixed with 100 M nitrocefin and various concentrations of BLI in reaction 
buffer and absorbance at 490 nm was measured immediately every two seconds for 180 sec on 
SpectraMax plate reader (“Molecular Devices”) at 37 oC. Resulting progression curves of OD490 
vs time at various BLI concentrations were imported into Prism software (“GraphPad”) and pseudo 
first-order rate constants kobs were calculated using the following equation: 
 
P=V0*(1-e-kobs*t)/kobs, where Vo - uninhibited KPC-2 rate. Kobs values calculated at various 
vaborbactam concentrations were fitted in the following equation 
kobs=k-2+k2/K*[I]/(1+[NCF]/Km(NCF)), where 
k2/K - inactivation constant 
[I] – inhibitor concentration 
[NCF] – nitrocefin concentration 
Km(NCF) - Michaelis constant of NCF for KPC-2 
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4.5.11 Determination of Koff rates of enzyme activity recovery after KPC-2 and 
mutants’ inhibition by vaborbactam 
 Purified enzyme at 1 M concentration in reaction buffer was mixed with BLIs at 8-fold 
higher concentration than its stoichiometry ratio (determined in preliminary stoichiometry 
experiments). After 30 min incubation at 37 oC, reaction mixture was diluted 30,000-fold in 
reaction buffer and 100 L of diluted enzyme was mixed with 100 L of 400 M NCF in reaction 
buffer. Absorbance at 490 nm was recorded every minute during 4 h at 37 oC. Resulting reaction 
profiles were fitted into the following equation using Prism software (GraphPad) to obtain Koff 
values: P=Vs*t+(Vo-Vs)*(1-e-koff*t)/koff, where 
Vs – uninhibited enzyme velocity, measured in the reaction with enzyme and no inhibitor 
Vo – completely inhibited enzyme velocity, measured in the reaction with no enzyme and NCF 
only 
 
4.5.12 Crystallization experiments 
KPC-2 was expressed and purified as previously described [33]. Vaborbactam was dissolved in 
DMSO as a 200 mM stock solution and stored at -20 oC. Prior to crystallization setup, 5 mM 
vaborbactam was gently mixed with 11.6 mg/mL His-tag KPC-2 and incubated at room 
temperature for 5 min. Crystal trays for His-tag KPC-2 were set with 500 L wells and crystal 
drops consisted of 0.5 L protein and 1 L of crystallization solution (2 M ammonium sulfate and 
5% (v/v) ethanol). Droplets (1.5 L) were microseeded with 0.5 L of diluted seed stock. 
Crystallization trays were stored at 20 oC and crystals typically appeared within 5 days. Crystals 
were cryo-protected in mother liquor supplemented with 20% (v/v) glycerol and flash frozen with 
liquid nitrogen. 
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4.5.13 Data collection and structure determination 
Data for the KPC-2/vaborbactam structure was collected at the Advanced Photon Source (APS) 
beamline 19-ID. Diffraction data was indexed and integrated with iMosflm [56] and scaled with 
SCALA [57] from the CCP4 suite [58]. Phasing was performed using molecular replacement with 
the program Phaser [59] with the KPC-2 structure (PDB ID code: 5UL8 [33]). Structure refinement 
was performed using phenix.refine [60] in the Phenix suite [61] and model building in WinCoot 
[62]. The program eLBOW [63] in the Phenix suite was used to obtain geometry restraint 
information. The final model quality was assessed using MolProbity [64]. Figures were prepared 
using PyMOL 1.3 (Schrödinger) [65]. 
 
4.6 Note to Reader #1 
The binding kinetic experiments, MIC assays, and mutagenesis studies were contributed 
by The Medicines Company, which are the developers of vaborbactam and Vabomere 
(vaborbactam/meropenem). 
 
4.7 Note to Reader #2 
Supplementary figures (Fig. S4.1, S4.2, S4.3, S4.4, and S4.5) and tables (Table S4.1 and 
S4.2) are located in Appendix 2. 
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Clavulanic acid Avibactam Tazobactam 
Figure 4.1. Chemical structures of clinically available and promising new BLIs.  
S02030 Vaborbactam 
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Figure 4.2. Vaborbactam bound to KPC-2 active site. (A) The unbiased F
o
-F
c
 map (gray) of vaborbactam in the active site 
of KPC-2 contoured at 3 . KPC-2 residues and the vaborbactam molecule are green. HB are depicted by dashed lines. (B) 
Superimposition of KPC-2/vaborbactam (green) and KPC-2 apo (PDB ID code: 5UL8, purple). 
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Figure 4.3. Superimposition of KPC-2/vaborbactam and CTX-M-15/vaborbactam structures. KPC-
2/vaborbactam (green) with CTX-M-15/vaborbactam (PDB ID code: 4XUZ, purple). Red arrow indicates a 
backbone shift. 
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Figure 4.4. Vaborbactam induces a backbone conformational changes near the oxyanion hole. (A) CTX-M-15 apo 
(PDB ID code: 4HBT, purple), avibactam (PDB ID code: 4HBU, blue), and vaborbactam (PDB ID code 4XUZ, green). 
(B) KPC-2 apo (PDB ID code: 5UL8, purple), avibactam (PDB ID code: 4ZBE, blue), and vaborbactam (green). 
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BLI Stoichiometry of KPC-2 inhibition 
Vaborbactam 1 
Avibactam 1 
Tazobactam >64 
Clavulanic acid >64 
Table 4.1. Stoichiometry of KPC-2 inhibition by various BLIs 
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-Lactamase BLI k2/K (M
-1* s-1) koff, s
-1 Residence time, min Kd, nM 
KPC-2 Vaborbactam 7.3 X 103 0.000017 992 2.3 
KPC-2 S130G Vaborbactam 6.7 X 104 0.0044 3.8 66 
KPC-2 Avibactam 1.3 x 104 0.00022 77 17 
KPC-2 S130G Avibactam 9.0 ND ND ND 
CTX-M-15 Vaborbactam 2.3 x 104 0.00088 19 38 
Table 4.2. Kinetic parameters of inhibition of KPC-2 and CTX-M-15 by vaborbactam and avibactam  
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 Aztreonam MIC (g/mL) in the presence of varied concentrations of vaborbactam (g/mL) 
-Lactamase 0 0.15 0.3 0.6 1.25 2.5 5 10 MPC16 
 
KPC-2 16 0.25 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.15 
CTX-M-15 8 8 4 2 1 0.5 0.25 ≤0.125 2.5 
Table 4.3. Concentration-response of aztreonam potentiation by vaborbactam against engineered E. coli 
strains expressing KPC-2 and CTX-M-15 
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   Antibiotic MIC (g/mL) in the presence of various concentrations of BLIs (g/mL)  
Plasmid BLI Antibiotic 0 1 2 4 8 16 32 
KPC-2  Vaborbactam Carbenicillin 1024 64 16 8 4 2 1 
KPC-2 S130G Vaborbactam Carbenicillin 128 4 2 1 ≤0.5 ≤0.5 ≤0.5 
KPC  Avibactam Carbenicillin 1024 64 64 32 16 8 2 
KPC-2 S130G Avibactam Carbenicillin 128 128 128 64 64 64 32 
KPC-2  Vaborbactam Piperacillin 128 1 0.5 0.25 ≤0.13 ≤0.13 ≤0.13 
KPC-2 S130G Vaborbactam Piperacillin 128 2 0.5 0.25 0.25 ≤0.13 ≤0.13 
KPC-2  Avibactam Piperacillin 128 2 1 0.5 0.25 ≤0.13 ≤0.13 
KPC-2 S130G Avibactam Piperacillin 128 128 64 64 64 32 16 
Table 4.4. Concentration-response of carbenicillin and piperacillin potentiation by vaborbactam and avibactam 
against KPC-2 and KPC-2 S130G producing strain of P. aeruginosa 
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Chapter 5: 
 
Leveraging Protein Promiscuity in Ligand Binding to Develop Broad-Spectrum  
 
Carbapenemase Inhibitors 
 
5.1 Overview 
 Gram-negative bacterial pathogens expressing the serine -lactamase KPC-2 and the 
MBLs NDM-1 and VIM-2 threaten the clinical utility of all -lactam antibiotics. These enzymes 
have a broad-substrate profile, most likely due to the hydrophobicity and flexibility of their active 
sites, particularly for the metalloenzymes. Here I demonstrate that this promiscuity in ligand 
recognition may expose a potential weakness that can be exploited through rational drug design. 
Using a fragment-based approach, I report the identification of a series of phosphonate compounds 
that represent the first cross-class, non-covalent inhibitors of KPC-2, NDM-1, and VIM-2. 
Although my lead optimization specifically targeted KPC-2, the increase in KPC-2 inhibition was 
mirrored by improvement in activity against NDM-1, and particularly VIM-2. These findings 
provide novel chemical scaffolds for antibiotic development against bacteria co-producing serine 
carbapenemases and MBLs, and suggest that protein promiscuity can be leveraged in developing 
high affinity cross-class inhibitors. 
 
5.2 Introduction 
-Lactam antibiotics are among the oldest and most widely used drugs used to treat a 
diverse range of bacterial infections [1]. The most common mechanism of -lactam antibiotic 
 113 
 
resistance involves the production of -lactamase enzymes that hydrolyze them [2]. There are four 
classes of -lactamases (A, B, C, and D), which differ from one another based on their amino acid 
sequence and mechanism of action. Class A, C, and D -lactamases are active-site serine enzymes, 
whereas class B -lactamases require one or two zinc ions for activity [3, 4]. 
Carbapenems (e.g., imipenem, meropenem, doripenem, and ertapenem) are the most potent 
-lactam antibiotics, and are often considered the “last-resort antibiotics” used to treat multi-drug 
resistant infections [5-7]. Unfortunately, the recent emergence of CRE and multi-drug resistant P. 
aeruginosa threatens the use of all -lactam antibiotics. CRE infections are associated with high 
rates of morbidity and mortality worldwide due to limited treatment options [8]. The CDC 
estimates that there are over 9,000 cases of CRE and 6,700 cases of multi-drug resistant P. 
aeruginosa infections a year in the United States [9]. Carbapenem resistance in CRE and P. 
aeruginosa is usually mediated by the production of carbapenem hydrolyzing enzymes known as 
carbapenemases, and/or by the combination of porin loss and hyperproduction of AmpC or an 
ESBL [10-12]. Most carbapenemases are broadly promiscuous enzymes that can catalyze the 
hydrolysis of multiple -lactam substrates including not only carbapenems, but also penicillins, 
cephalosporins, monobactams, and -lactam-based BLIs [7, 13]. These enzymes belong to either 
class A and D -lactamases (serine carbapenemases) or molecular class B (MBLs) [14]. Of notable 
health concern is the serine carbapenemase KPC-2 (class A), and the MBLs NDM-1 and VIM-2 
(class B), all of which are commonly isolated from CRE, P. aeruginosa, and other Gram-negative 
pathogens [13]. 
To address the growing problem of -lactam antibiotic resistance, numerous inhibitors 
have been developed to target -lactamases. However, most of these inhibitors target serine -
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lactamases and none in clinical use are active against both serine -lactamases and MBLs [13]. In 
general, the BLIs clavulanic acid, sulbactam, and tazobactam display potent activity against many 
class A -lactamases, with only limited activity against class C and D -lactamases, and no activity 
against KPC-2 and class B -lactamases [13, 15]. Recently, novel BLIs such as avibactam and 
vaborbactam (Fig. 5.1) have been demonstrated to inhibit the class A, C, and D -lactamases, 
including KPC-2, but possess no activity against MBLs [16-18]. Additionally, a naturally produced 
polyamino acid called Aspergillomarasmine A (AMA) (Fig. 5.1) derived from the mold 
Aspergillus versicolor has been observed to potently inhibit MBLs by acting as a chelating agent 
[19, 20]. Unfortunately, there are some drawbacks to AMA, which include its non-specific 
inhibition as demonstrated by its ability to chelate essential metal ions required by human 
metalloproteins, and its inability to inhibit serine -lactamases [19, 21]. Therefore, there is a 
serious unmet medical need for the development of novel compounds that can simultaneously 
target serine carbapenemases and MBLs commonly encountered in multi-drug resistant bacterial 
infections. 
Developing a single cross-class inhibitor that can inactivate both serine carbapenemases 
and MBLs has long been considered a challenging feat due to the structural and mechanistic 
heterogeneity between these enzymes, as well as the difficulties associated with antibacterial 
development in general [13, 22-24]. In the last decade, fragment-based approaches have become 
an effective approach for inhibitor discovery against challenging targets, yet key questions remain 
as for its utility in developing cross-class carbapenemase inhibitors, in both lead identification and 
optimization [25-27]. Firstly, although fragments usually have low specificity, there has been no 
report of fragment compounds displaying activity against both serine carbapenemases and MBLs, 
with the majority of drug discovery efforts focusing on only one of the two groups of enzymes. 
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Secondly, FBDD has mainly been applied to a single target, or multiple targets with high structural 
similarity. It is unknown whether such an approach can be successfully implemented against two 
groups of enzymes with as much structural and mechanistic differences as serine carbapenemases 
and MBLs. This is particularly true for the lead-optimization process, when inhibitors also display 
increased specificity [27]. 
In this study, I demonstrate that a fragment-based and structure-guided approach can be 
successfully implemented in developing cross-class inhibitors against serine carbapenemases and 
MBLs. The newly identified inhibitors provide novel scaffolds for antibiotic development 
targeting carbapenem resistance, as well as valuable insights into how the unique broad-spectrum 
activity of carbapenemases can be exploited in FBDD against multiple targets. 
 
5.3 Results and Discussion 
 
5.3.1 Structure-based inhibitor discovery against the serine carbapenemase KPC-2 
My investigation into a broad-spectrum serine carbapenemase and MBL inhibitor began 
with molecular docking to KPC-2. This was due to the relatively abundant knowledge of serine -
lactamases and the need for novel inhibitor chemotypes against KPC-2 in spite of the latest drug 
discovery efforts (e.g., avibactam, relebactam, vaborbactam) [27, 28]. Docking to the ZINC 
database of commercially available compounds led to the identification of a phosphonate based 
compound 1 (Table 5.1). 
Using a biochemical assay with nitrocefin as a substrate, we observed compound 1 to be a 
moderate inhibitor of KPC-2 (Ki = 32.9 M). To improve compound activity, and to probe the 
contributions of various functional groups to binding, five analogs were purchased and tested 
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against KPC-2. All the purchased compounds displayed micromolar potency against KPC-2, 
ranging from a Ki of 1.4 M to 154.4 M (Table 5.1). Compounds 2 and 3 had similar Ki’s of 13.4 
M and 15.3 M, respectively. Compounds 4 and 5 are regioisomers with one methyl group 
attached to either the C6 atom (compound 5) or the C7 atom (compound 4). Compound 5 had a Ki 
of 154.4 M against KPC-2, whereas compound 4 had a Ki of 39.5 M. This suggests that KPC-
2 prefers the methyl substituent on the C7 atom as opposed to the C6 atom. This trend becomes 
more apparent when comparing compounds 1 and 6, which are also regioisomers, having two 
methyl groups, one attached to C6 and C7 (compound 1) or attached to C5 and C7 (compound 6). 
Compound 6 had the best activity with a Ki of 1.4 M. As a result, SAR studies were focused on 
derivatives of compound 6 in subsequent chemical synthesis efforts. 
The synthesized compounds 7 through 10, like compound 6, had various substituents 
attached to C5 and C7 to investigate how they would impact KPC-2 inhibition. At both C5 and C7 
positions, increasing the size of the substitution (from –F, -CH3 to –Br) appears to improve the 
inhibition, except for compound 7, with a methoxy group at C5. This replacement resulted in a 
decrease in activity as compared to compound 6 (Ki = 5.7 M). The bromine substitution at C5, 
compound 9, resulted in a potent inhibitor of KPC-2 (Ki = 0.47 M). 
 I was interested in seeing if changing the coumarin scaffold to a similar quinolone and 
quinoline scaffold, would retain activity against KPC-2, due to the unfavorable pharmacokinetic 
properties often associated with the coumarin ring. Three quinolone derivates (compounds 11, 12, 
13) and two quinoline derivatives (compounds 14, 15) were synthesized and tested for inhibition. 
Out of all the quinolone derivatives, compound 11 had the lowest level of inhibition (Ki = 122 
M), possibly due to the lack of substituents on the C5 and C7 atoms. A similar result was seen 
for compound 12 (Ki = 79.2 M), which also had no substituents on the C5 and C7 atoms, but 
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possessed a methyl group attached to the N1 atom. Compound 13 was the most potent quinolone 
derivative (Ki = 4.2 M), demonstrating similar activity to compound 6, due to both having methyl 
groups located on C5 and C7. The two quinoline derivatives (compounds 14, 15) had the lowest 
level of activity against KPC-2, possessing Ki’s of 447.1 M and 414.5 M, respectively. 
Together, these results suggest that the exact chemical composition of a coumarin ring itself is not 
essential for compound activity and demonstrates the potential of these compounds for further 
development. 
To better understand the structural basis of inhibition of the phosphonate based compounds, 
I determined complex crystal structures with compounds 1, 2, 3, 6, and 9 (e.g., 1, 6, 9 Fig. 5.2 and 
2, 3 Fig. S5.1) at resolutions of 1.50 Å and better. In the binding site, the conformation of the 
inhibitors was unambiguously identified in the initial Fo-Fc electron density difference map 
contoured at 2  (Fig. 5.2). For all the KPC-2 complex structures, the phosphonate moiety 
establishes HBs with Ser70, Ser130, Thr235, and Thr237. In addition, the phosphonate group 
forms a water-mediated HB with the backbone carbonyl of Thr216, and the carbonyl oxygen of 
the inhibitors form a water-mediated HB with Arg220 and His274. The coumarin ring system 
forms a pi-pi stacking interaction with Trp105. When examining the biochemical activities of 
compounds 1, 6, and 9, it becomes apparent why compounds 6 and 9 have much better activity 
against KPC-2 than compound 1. Moving the C6 methyl group (1) to the C5 position (6 and 9) 
allows the coumarin ring to swing towards Trp105, a position that would otherwise cause steric 
clashes between the C6 methyl group in 1 and Asn132. Concomitantly, there is a conformational 
change in Trp105, that allows it to flip upward and closer to the ring system, forming stronger 
hydrophobic interactions. In addition, the C5 substitution in compounds 6 and 9 also contributes 
to non-polar interactions with Trp105. 
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5.3.2 Inhibition of the MBLs NDM-1 and VIM-2 
Expanding my inhibitor discovery efforts to two clinically relevant MBLs, NDM-1 and 
VIM-2, I tested a select list of the phosphonate based coumarin, quinolone, and quinoline 
compounds that displayed activity against KPC-2. Compound 6 was the most potent of the 
compounds against NDM-1 (Ki = 33.8 M) and VIM-2 (Ki = 0.82 M). As observed in KPC-2, 
NDM-1 and VIM-2 also prefer substituents on C5 and C7 for effective inhibition. This is reflected 
in compounds with C5 and C7 substituents (6, 8, 9, and 13) having greater potency than 
compounds lacking C5 and C7 substituents (11, 12, 14, 15) (Table 5.1). Interestingly, a fluorine 
atom located on either C5 (compound 10) or both C5 and C7 (compound 8) appears to negatively 
influence NDM-1 inhibition. This is demonstrated by no inhibition observed with compound 8 and 
decreased inhibition of compound 10, as compared with compound 9 that has a bromine atom on 
C5 instead of a fluorine. 
NDM-1 complex structures were determined with compounds 1, 2, 3, 7, 8, 9, 11, 12, 13, 
and 14, and VIM-2 complex structures with compounds 8 and 14. All structures were solved at 
resolutions of 1.75 Å and better (Fig. 5.3, Fig. S5.2). In the binding site, the conformation of the 
inhibitors was unambiguously identified in the initial Fo-Fc electron density difference map 
contoured at 2  (Fig. 5.3, Fig. S5.2). The phosphonate group of each inhibitor coordinates with 
both zinc ions in NDM-1 and VIM-2, displacing a hydroxide ion that is essential to catalysis [29]. 
For NDM-1, the phosphonate based coumarin, quinolone, and quinoline compounds form common 
interactions within the active site. These interactions include the phosphonate moiety forming HBs 
with Asn220 and with Asp124, which also forms a similar interaction with the hydroxide ion in 
the apoenzyme; and the ring systems of the compounds forming pi-sigma interactions with Met67, 
as well as non-polar interactions with Trp93 and Val73. Another commonly observed interaction 
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is a pi-pi T-shaped interaction with Phe70 that every compound forms with NDM-1 except 
compound 13.     
Aside from the shared binding features, one key structural variation among the binding 
poses of these compounds is the two different orientations of the ring system: one pointing the ring 
carbonyl group away from Val73 (pose 1, e.g., compound 1, Fig. 5.3A) and the other towards it 
(pose 2, e.g., compound 13, Fig. 5.3B). Pose 1 is favored by compounds with substitution at the 
C6 position (e.g., 2, 3, Fig. S5.2) or at the O/N1 position (e.g., 11, 12, Fig. S5.2), in order to 
enhance interactions with Val73 (e.g., using the C6 methyl group of 1) or avoid unfavorable 
interactions with Phe70, respectively. The unfavorable interactions with Phe70 include both 
potential steric clashes in the case of the N1 methyl group in 12, and the inability to HB with water, 
in the case of the N1 hydrogen in 11. Pose 2 is favored by compounds with C5 substitutions for 
additional interactions with His122 (e.g., -F in 8, Fig. 5.3C; -Br in 9, Fig. 5.3G). In the case of 13, 
which has both C5 and N1 substitutions, pose 2 binding is observed in the active site, to increase 
interactions with His122, while Phe70 moves slightly away from the compound to avoid 
unfavorable interactions with the hydrogen at the N1 position.   
Similar to NDM-1, compound 8 in VIM-2 adopts pose 2, and its phosphonate group forms 
a HB with Asn210 and Asp118 (Fig. 5.3D). The ring system of compound 8 forms a pi-pi stacking 
interaction with Tyr67 and Trp87, and a pi-pi T-shaped interaction with His240, like the contacts 
between related compounds and Phe70/Trp93/His250 in NDM-1. Unique to VIM-2 is the presence 
of Arg205 near the active site, which can establish a HB with the carbonyl oxygen of compound 
8, which may result in tighter binding, particularly in comparison to NDM-1. Arg205 is also one 
of the reasons why two copies of compound 14 were observed in the active of VIM-2 (Fig. 5.3F). 
This is unlike any other inhibitors, where only one copy binds to the active site of KPC-2 or NDM-
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1. The first copy of compound 14 has the phosphonate group forming HBs with the Arg205 side 
chain and Asn210 backbone. The ring system forms a pi-pi T-shaped interaction with Tyr67 in 
addition to a pi-pi stacking interaction with the second copy of compound 14. The second copy 
binds in a way similar to 8, but is pushed away from Tyr67 by the first copy. The binding affinity 
of compound 8 (Ki = 3.3 M) is roughly 6-fold lower than compound 14 (Ki = 22.3 M). This 
may partially be explained by the more extensive interactions between compound 8 and the 
protein. It is possible that both copies of 14 are relevant to enzyme inhibition as there appears to 
be favorable interactions between the compounds as well, which can potentially enhance binding 
to the protein. 
 
5.3.3 Correlation of KPC-2, NDM-1, and VIM-2 inhibition 
When comparing the activities of the synthesized phosphonate based inhibitors against 
KPC-2 and VIM-2, a trend becomes apparent. These synthesized compounds represent the core 
phosphonate ring scaffold with and without decorations at both C5 and C7 positions. As inhibitors 
become more potent against KPC-2, they also demonstrate increasing potency against NDM-1 and 
VIM-2 (Fig. 5.4). The correlation reflects the similar binding features of both proteins and the 
relatively simple configuration of the compound, which reduces the likelihood of steric clashes. 
Nevertheless, it is a striking trend considering the design and synthesis of these compounds were 
originally intended for the SAR studies for KPC-2, based on the understanding of the commercially 
available analogs.   
The crystal structures of KPC-2 illustrate how the activity of the compounds are enhanced 
as additional functional groups are added to the core scaffold. Compared with the smallest 
compounds 14 and 15, the additional carbonyl group on 11 and 12 establishes new water-mediated 
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interactions with Arg220 and His274; the subsequent substitutions at C5 and C7 positions in 8, 
and particularly in 9, led to increased contacts with Leu167, Trp105, and neighboring residues. 
Similar observations were made in NDM-1 and VIM-2 complex structures. For NDM-1, the larger 
-Br of 9 makes new contacts with His122, while for VIM-2, the carbonyl group of 8 augments 
inhibitor binding through a HB with Arg205. 
 
5.3.4 Susceptibility of clinical isolates to compounds 9, 11, and 13 
To investigate the effects of these inhibitors on bacterial cells, compounds 9, 11, and 13 
were selected and tested (at 128 g/mL), in combination with the carbapenem antibiotic imipenem, 
against Gram-negative clinical isolates known to produce carbapenemases (Table 5.2). Compound 
9 restored susceptibility to imipenem in a K. pneumoniae strain producing KPC-2, and reduced the 
MIC by 64-fold. It also decreased the MIC for imipenem by 4-fold in an NDM-1 producing E. coli 
strain, and 2-fold in an NDM-1 producing K. pneumoniae strain. Compound 9 did not have any 
activity against NDM-1 producing E. cloacae. Compared to KPC-2, the lower cell-based activity 
of 9 against NDM-1 correlates with the different in vitro activities in biochemical testing. The 
variation among different bacterial strains underscores the influence of other biological factors on 
the cell-based activity of these inhibitors. This is further demonstrated by the lack of activity of 9 
against a VIM-2 producing P. aeruginosa strain, even though our nitrocefin inhibition assays 
demonstrated compound 9 to be a micromolar inhibitor of VIM-2 (Ki = 1.3 M). Compound 11 
was less effective than compound 9 in reducing the MIC of imipenem against the KPC-2 producing 
K. pneumoniae. It displayed similarly low activity, or no effect against NDM-1 producing E. coli, 
K. pneumoniae, and E. cloacae. Compound 13 was comparable to compound 9 at reducing the 
MIC of imipenem by 64-fold in KPC-2 producing K. pneumoniae, and 4-fold in NDM-1 producing 
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E. coli, but was not able to reduce the MIC in NDM-1 producing K. pneumoniae/E. cloacae, and 
VIM-2 producing P. aeruginosa. Overall these results suggest that the phosphonate inhibitors were 
able to cross the cell envelope and inhibit the carbapenemases produced by pathogenic Gram-
negative bacteria. 
 
5.4 Conclusions 
Serine carbapenemases and MBLs produced by Gram-negative pathogens are a serious 
threat to human health due to their multi-drug resistant nature. The development of an inhibitor 
that can target both serine carbapenemases and MBLs is imperative. My biochemical, X-ray 
crystallographic, and cell-based studies have demonstrated, for the first time, that rational design 
of a cross-class, non-covalent, broad-spectrum inhibitor against serine carbapenemases and MBLs 
is an achievable task. More importantly, my results provide valuable chemical and structural 
information, as well as important insights for future drug discovery efforts against these enzymes. 
My inhibitor discovery efforts focused on fragment-based approaches, which are uniquely 
suitable for identifying novel inhibitor chemotypes for difficult bacterial targets. Nevertheless, as 
evidenced by the lack of published results in this area, identifying suitable cross-class fragment 
inhibitors for carbapenemases is challenging, particularly for chemical scaffolds that enable lead 
optimization for both groups of enzymes. The phosphonate compounds provide a promising novel 
fragment chemotype for this purpose, and represent the first non-covalent inhibitors with 
comparable binding affinities against both serine -lactamases and MBLs. In both KPC-2 and 
NDM-1/VIM-2, the inhibitors reside in an area usually occupied by the -lactam core of the 
substrates, and is thus essential for enzyme activity (Fig. 5.5). In KPC-2, the phosphonate moiety 
is placed in a subpocket formed by Ser130, Thr235, and Thr237, which also happens to interact 
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with the C3’/4’ carboxylate group of the -lactam substrate [30]. In NDM-1/VIM-2, the 
phosphonate group interacts with both zinc ions and neighboring residues important for binding to 
the same substrate C3’/4’ carboxylate group, as well as the -lactam carbonyl group, which is 
converted to a carboxylate group after the hydrolysis reaction catalyzed by the -lactamases [4, 
13]. The cell-based activity of these inhibitors further supports these compounds’ potential as lead 
scaffolds for antibiotic development. In addition, the observation of an acetate molecule in the 
NDM-1 active site informs future fragment-based lead-optimization efforts, by highlighting an 
underutilized binding hot spot that also contributes to the binding of the C3’/4’ carboxylate group 
in previous NDM-1 complexes [31, 32].   
Most significantly, my results have underscored the versatility of carbapenemases in ligand 
binding, and demonstrated that this feature can be a double-edged sword for carbapenemases, 
presenting a unique opportunity for drug discovery. The relative open and hydrophobic features of 
carbapenemase active sites, particularly in the metalloenzymes, have led to the hypothesis that 
these binding surfaces may lead to increased druggability [30]. Our crystal structures have 
illustrated the important contributions of a number of hydrophobic residues to ligand binding, such 
as Trp105/Leu167 in KPC-2, Val73/Trp93/Met67/Phe70 in NDM-1, and Trp87/Tyr67 in VIM-2. 
In addition, the conformational variation of the protein residues and ligand binding poses observed 
in our structures suggest that residue flexibility and the relative openness of the active site affords 
the carbapenemases important adaptability in binding to small molecules. Examples of protein 
structural flexibility include: Trp105 in KPC-2, as shown by its varied conformations in binding 
to compounds 1 and 6, and particularly in comparison to the more rigid Tyr105 in other class A 
serine -lactamases [33-36]; Phe70 and the surrounding loop in NDM-1, as indicated by their 
movement in binding to compound 13; and Arg205 in VIM-2, adopting different conformations 
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binding to compounds 8 and 14, and making important HBs in both cases. The relative 
openness/flat features of MBLs is partially demonstrated by how two drastically different ligand 
conformations, caused by flipping of the ring system (e.g., 1 vs 13, Fig. 5.3A, B), can both be 
accommodated in NDM-1 active site, allowing the ligand to maximize its contacts with the protein 
while having minimal steric clashes. 
These unique structural features endow carbapenemases with a certain level of ligand 
binding promiscuity. The openness of the active site reduces the chances of steric clashes with 
small molecules, whereas increased hydrophobicity compensates the diminished shape 
complementarity. Albeit to a lesser extent, these properties are reminiscent of other proteins 
capable of binding to a wide range of ligands, such as efflux pumps [37, 38]. For carbapenemases, 
such qualities may explain their ability to bind and hydrolyze nearly all -lactam antibiotics, but 
may also expose a weakness to novel inhibitor binding. For drug discovery against these enzymes, 
this is particularly valuable for the lead optimization process. The correlation between the inhibitor 
activity, particularly with VIM-2 and KPC-2, is very informative, considering that the compounds 
were designed and synthesized to target KPC-2. The hydrophobicity, flexibility, and relative 
flatness of the VIM-2 active site enables it to accommodate and adapt to the ligand to maximize 
the interactions, as the size and complexity of the ligand increases. This correlation is also 
especially striking when compared to previous studies on CTX-M class A and AmpC class C -
lactamases. Both are serine-based enzymes and have more active site similarities than those shared 
by KPC-2 and VIM-2 [39]. In the previous fragment-based inhibitor discovery efforts, the starting 
fragment inhibitors have low specificity with mM range affinities against both enzymes. But as 
the compound size rises and the binding affinity against CTX-M-9 improves to mid-low M, the 
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specificity significantly increases with the binding affinity, remaining at mM or undetectable for 
AmpC. 
There have been previous efforts to develop cross-class inhibitors of serine -lactamases 
and MBLs, including the most recent success of a series of cyclic boronate compounds [22, 40, 
41]. However, these inhibitors usually use two different mechanisms to inhibit serine -lactamases 
and MBLs separately, and provide relatively little information on rational design of novel cross 
class inhibitors, particularly concerning the challenges in the lead optimization process. In the case 
of cyclic boronates, they rely on the reactivity of boron groups to form covalent bonds with the 
catalytic serine of serine -lactamases, and consequently achieve high binding affinity. In 
comparison, the boronates behave as non-covalent inhibitors for MBLs. As a result, the lead 
optimization process would only need to focus on increasing the binding affinity against the 
metalloenzymes, with some consideration of avoiding steric clashes in serine -lactamase active 
sites.    
 In conclusion, my studies have uncovered novel cross-class inhibitors against two groups 
of clinically important carbapenemases. Together with the new insights into ligand binding by 
these enzymes and FBDD, these compounds provide a promising strategy to develop novel 
antibiotics against -lactam resistance in bacteria. 
 
5.5 Materials and Methods 
 
5.5.1 KPC-2 expression and purification. 
KPC-2 was expressed and purified as previously described [30]. 
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5.5.2 NDM-1 expression and purification 
The gene encoding NDM-1 (residues 29-270) was cloned into the pET-SUMO vector with 
an N-terminal SUMO-tag. The plasmid containing SUMO-NDM-1 was transformed into E. coli 
BL21 (DE3) cells. For SUMO-tag NDM-1, bacteria were grown overnight at 30 oC with shaking 
in 50 mL LB broth supplemented with 100 g/mL ampicillin. Two liters of LB broth supplemented 
with 100 g/mL ampicillin were each inoculated with 10 mL of overnight bacterial culture. 
Cultures were then grown at 37 oC until an OD600 of 0.6-0.7. Protein expression was then initiated 
by the addition of IPTG (final concentration 0.5 mM), followed by growth for 16 h at 20 oC. Cells 
were pelleted by centrifugation and stored at -80 oC until further use.  
The SUMO-tag NDM-1 -lactamase was purified by nickel affinity chromatography and 
gel filtration. Briefly, the cell pellets were thawed and re-suspended in 40 mL of buffer A (20 mM 
HEPES pH 7.4, 0.5 M NaCl, 20 mM imidazole) with one complete protease inhibitor cocktail 
tablet (Roche) and disrupted by sonication, followed by ultracentrifugation to clarify the lysate. 
After ultracentrifugation, the supernatant was passed through a 0.22 m filter before loading onto 
a 5 mL HisTrap HP affinity column (GE Healthcare Life Sciences, USA) pre-equilibrated with 
buffer A. SUMO-tag NDM-1 was eluted by a linear imidazole gradient (20 mM to 500 mM). 
Fractions were analyzed by SDS-PAGE. Fractions containing SUMO-tag NDM-1 were buffer 
exchanged into 20 mM HEPES pH 7.0, 100 mM NaCl. Cleavage of the SUMO-tag was then 
carried out with ULP-1 protease overnight at room temperature and then concentrated using a 10k 
NMWL Amicon Ultra-15 Centrifugal Filter Unit. The sample was then loaded back onto a nickel 
affinity column and the flow through was collected, containing the untagged NDM-1. NDM-1 was 
concentrated and loaded onto a gel filtration column (GE Healthcare Life Sciences) pre-
equilibrated with 50 mM HEPES, 150 mM NaCl, and 50 M ZnSO4. Protein concentration was 
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determined by absorbance at 280 nm using an extinction coefficient of 27,960. SDS-PAGE 
analysis indicated that the eluted protein was more than 95% pure. 
 
5.5.3 VIM-2 expression and purification. 
The gene encoding VIM-2 (residues 27-266) was custom synthesized and inserted into a 
vector with an N-terminal His-tag. The plasmid containing His-tag VIM-2 was transformed into 
Rosetta2 (DE3) E. coli cells. For His-tag VIM-2, bacteria were grown overnight at 30 oC with 
shaking in 50 mL LB broth supplemented with 50 g/mL kanamycin. Two liters of terrific broth 
supplemented with 50 g/mL kanamycin were each inoculated with 10 mL of overnight bacterial 
culture. Cultures were then grown at 37 oC until an OD600 of 0.6-0.7. Protein expression was then 
initiated by the addition of IPTG (final concentration 0.5 mM), followed by growth for 16 h at 20 
oC. Cells were pelleted by centrifugation and stored at -80 oC until further use. 
VIM-2 was purified by nickel affinity chromatography, anion exchange, and gel filtration 
chromatography. Briefly, the cell pellets were thawed and re-suspended in 40 mL of buffer A (50 
mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole, 50 M ZnSO4) with one complete protease 
inhibitor cocktail tablet (Roche) and disrupted by sonication, followed by ultracentrifugation to 
clarify the lysate. After ultracentrifugation, the supernatant was passed through a 0.22 m filter 
before loading onto a 5 mL HisTrap HP affinity column (GE Healthcare Life Sciences, USA) pre-
equilibrated with buffer A. VIM-2 was eluted by a linear imidazole gradient (20 mM to 500 mM). 
Fractions were analyzed by SDS-PAGE. Fractions containing VIM-2 were buffer exchanged into 
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM DTT. Cleavage of the His-tag was then carried out 
with TEV protease overnight at room temperature and then concentrated using a 10k NMWL 
Amicon Ultra-15 Centrifugal Filter Unit. The sample was then loaded back onto a nickel affinity 
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column and the flow through was collected, containing the untagged VIM-2. VIM-2 was then 
subjected to anion exchange chromatography, using a linear gradient from buffer A (20 mM Tris-
HCl pH 7.5) to buffer B (20 mM Tris-HCl pH 7.5, 1 M NaCl). VIM-2 was concentrated and loaded 
onto a gel filtration column (GE Healthcare Life Sciences) pre-equilibrated with 50 mM HEPES 
pH 7.0, 150 mM NaCl, 50 M ZnSO4. Protein concentration was determined by absorbance at 280 
nm using an extinction coefficient of 25,669. SDS-PAGE analysis indicated that the eluted protein 
was more than 95% pure. 
 
5.5.4 Molecular docking 
The program DOCK 3.5.4 [42] was used to screen the fragment subset of the ZINC 
database of small molecules [43], using an in-house apo KPC-2 structure as a receptor template. 
The conserved catalytic water was left in the active site, while all other waters were removed. 
Docking was performed as previously described [39]. 
 
5.5.5 Steady-state kinetic analysis 
Steady-state kinetic parameters were determined by using a Biotek Cytation Multi-Mode 
Reader. For KPC-2, each assay was performed in 100 mM Tris-HCl pH 7.0, 0.01% Triton X-100 
at 37 oC. Vmax and Km were determined from initial steady-state velocities from nitrocefin read at 
a wavelength of 486 nm. The kinetic parameters were obtained using the non-linear portion of the 
data to the Henri-Michaelis (equation 1) using SigmaPlot 12.5. 
V= Vmax [S]/(Km + [S])                                                          (1) 
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IC50, defined as the inhibitor concentration that results in a 50% reduction of nitrocefin (20 m) 
hydrolysis was determined by measurements of initial velocities after mixing 1 nM of KPC-2 with 
increasing concentrations of inhibitors. The inhibition constant (Ki) was calculated according to 
equation 2: 
 
Ki= IC50/([S]/Km + 1)               (2) 
 
For NDM-1 and VIM-2, the procedures were the same as above except the assay was performed 
in 50 mM HEPES pH 7.2, 50 M ZnSO4, 0.01% Triton X-100, 1 g/mL bovine serum albumin 
(BSA). 
 
5.5.6 Crystallization and soaking experiments 
KPC-2 was crystallized as described previously [30]. KPC-2 crystals were soaked in 1.44 
M sodium citrate containing 10 mM inhibitor for approximately 2 h. KPC-2 crystals were then 
cryoprotected in a solution containing 1.15 M sodium citrate, 20% (v/v) glycerol and flash-frozen 
in liquid nitrogen. Crystals of NDM-1 were grown at 20 °C using hanging-drop vapor diffusion. 
Protein solutions (10-20 mg/mL) in 50 mM HEPES, 150 mM NaCl, and 50 M ZnSO4 were mixed 
1:1 (v/v) with reservoir solution containing 50 mM potassium phosphate dibasic, 10 mM CaCl2 
and 25% (w/v) PEG8000. Crystals typically formed in two days. To obtain the ligand bound 
structures, NDM-1 crystals were soaked in a solution of 50 mM sodium acetate pH 3.85, 25% 
(w/v) PEG8000 and 10 mM inhibitor for 1 h. The soaked crystals were cryo-protected in a solution 
containing 50 mM sodium acetate pH 3.85, 25% (w/v) PEG8000, and 20% (v/v) glycerol and 
flash-frozen in liquid nitrogen. Crystals of VIM-2 were grown at 20 °C using hanging-drop vapor 
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diffusion. Protein solutions (10-20 mg/mL) in 50 mM HEPES, 150 mM NaCl, and 50 M ZnSO4 
were mixed 1:1 (v/v) with reservoir solution containing 200 mM calcium acetate, 20% (w/v) 
PEG3350, and 1 mM TCEP. Crystals typically formed in two days. To obtain the ligand bound 
structures, VIM-2 crystals were soaked in a solution of 50 mM sodium acetate pH 3.85, 25% (w/v) 
PEG8000 and 10 mM inhibitor for 1 h. The soaked crystals were cryo-protected in a solution 
containing 50 mM sodium acetate pH 3.85, 25% (w/v) PEG8000, and 20% (v/v) glycerol and 
flash-frozen in liquid nitrogen. 
 
5.5.7 Data collection and structure determinations 
Data for the KPC-2, NDM-1, and VIM-2 complex structures were collected using 
beamlines 22-ID-D and 23-ID-D at the Advanced Photon Source (APS), Argonne, Illinois and 
beamline 8.3.1 at the Advanced Light Source (ALS), Berkeley, California. Diffraction data were 
indexed and integrated with iMosflm [44] and scaled with SCALA [45] from the CCP4 suite [46]. 
Phasing was performed using molecular replacement with the program Phaser [47] of the Phenix 
suite [48], with the KPC-2 structure (PDB ID code: 5UL8), NDM-1 (PDB ID code: 4TYF), and 
VIM-2 (PDB ID code: 4BZ3). Structure refinement was performed using phenix.refine [49] of the 
Phenix suite and model building in WinCoot [50]. The unbiased Fo-Fc electron density maps were 
generated prior to refinement with compound. The program eLBOW [51] in Phenix was used to 
obtain geometry restraint information. The final model qualities were assessed using MolProbity 
[52]. Figures were generated in PyMOL 1.3 (Schrödinger) in which structural alignments were 
generated using pairwise scores [53]. 
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5.6 Note to Reader #1 
 Supplementary figures (Fig. S5.1 and S5.2) are located in Appendix 3.  
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Figure 5.1. Clinical and pre-clinical serine carbapenemase and MBL inhibitors.  
Avibactam Vaborbactam Aspergillomarasmine A 
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Figure 5.2. X-ray crystal structures of KPC-2 bound to phosphonate inhibitors. (A) compound 1, (B) compound 6, and (C) 
compound 9. KPC-2 residues are colored gray, compounds are colored in green, and the unbiased Fo-Fc map is colored in gray and 
contoured at 2 . 
 
 134 
 
 
R205 
Y67 
W87 
H116 
H114 
H179 
D118 
C198 
H240 
Zn2 
Zn1 
(D) 
N210 
C208 
W93 
L65 
M67 
F70 
N220 
H122 
H189 
H120 
H250 
D124 
Zn2 
ACT 
Zn1 
(B) 
V73 
W93 
V73 
L65 
M67 F70 
C208 
H250 
D124 
Zn2 
H120 H189 
N220 
Zn1 
H122 
ACT 
(C) 
H250 
V73 
W93 
L65 
M67 
F70 
N220 
H189 H120 
C208 
D124 
ACT 
H122 
Zn1 
Zn2 
(A) 
H189 
N220 
F70 M67 
L65 
V73 W93 
C208 
H250 
D124 
H120 
H122 
Zn2 
Zn1 ACT 
(E) 
W87 
Y67 
R205 
H179 
H114 
H116 
C198 
H240 
D118 Zn2 
Zn1 
(F) 
N210 
H189 H120 
H122 
D124 
W93 
L65 
M67 
F70 
N220 
C208 
Zn2 
Zn1 
H250 
V73 
ACT 
(G) 
Figure 5.3. X-ray crystal structures of NDM-1 and VIM-2 bound to phosphonate inhibitors. (A) NDM-1 with 1. (B) NDM-1 with 
13. (C) NDM-1 with 8. (D) VIM-2 with 8. (E) NDM-1 with 14. (F) VIM-2 with 14. (G) NDM-1 with 9. Fo-Fc map is colored in gray 
and contoured at 2 . Acetate ion is labeled as ACT and colored in purple. 
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(B) 
Figure 5.4. Correlation of -lactamase inhibition. (A) KPC-2 vs. NDM-1 inhibition and (B) KPC-2 vs. 
VIM-2 inhibition with select phosphonate compounds. 
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Figure 5.5. Superimposition of phosphonate inhibitor and -lactam product complexes. 
Superimposition of (A) KPC-2/compound 9 and KPC-2/cefotaxime product. KPC-2/compound 9 
complex are colored in gray and green, respectively. KPC-2/cefotaxime product are both colored in 
blue. Superimposition of (B) NDM-1/compound 9 and NDM-1/ampicillin product. NDM-1/compound 
9 complex are colored in gray and green, respectively. NDM-1/ampicillin product are both colored in 
blue. 
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Compound # Structure MW Ki (KPC-2) M Ki (NDM-1) M Ki (VIM-2) M 
 
1  
 
268.2 
 
32.9 
 
44.3 
 
2.1 
 
2 
 
 
 
270.2 13.4 
 
123.7 
 
2.1 
 
3 
  
284.2 
 
15.3 
 
N/A 
 
N/A 
 
4 
  
254.2 
 
39.5 
 
N/A 
 
N/A 
 
5 
 
 
 
 
254.2 
 
154.4 
 
N/A 
 
N/A 
 
6 
 
 
 
 
268.2 
 
 
1.4 
 
33.8 
 
0.82 
 
7 
  
284.2 
 
5.7 
 
N/A 
 
N/A 
 
8 
 
 
 
 
276.1 
 
8.9 
 
No inhibition 
 
3.3 
 
9 
 
 
 
333.1 
 
0.47 
 
65.4 
 
1.3 
 
10 
 
 
 
272.2 
 
3.3 
 
230.2 
 
3.3 
 
11 
  
239.2 
 
122 
 
190.2 
 
6.4 
 
12 
  
253.2 
 
79.2 
 
81.0 
 
7.5 
 
13 
  
267.2 
 
4.2 
 
56.2 
 
3.4 
 
14 
  
223.2 
 
447.1 
 
741.3 
 
22.3 
 
15 
  
223.2 
 
414.5 
 
No inhibition 
 
30.3 
Table 5.1. Nitrocefin inhibition assay of phosphonate compounds tested against KPC-2, NDM-1, and VIM-2 
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E. coli  NDM-1 8 2/128 2/ 128 2/128 
K. pneumoniae  KPC-2 64 1/128 4/ 128 1/128 
K. pneumoniae  NDM-1 >64 32/ 128 32/ 128 64/ 128 
E. cloacae  NDM-1 2 2/128 2/ 128 2/128 
P. aeruginosa  VIM-2 >64 >64/ 128 >64/128 >64/ 128 
Table 5.2. In vitro activity of phosphonate compounds when combined with imipenem. Compounds 9, 11, and 13 were 
tested at 128 g/mL fixed concentration with imipenem against KPC-2, NDM-1, and VIM-2 producing bacteria 
 139 
 
5.7 References 
1. Cho, H., Uehara, T., & Bernhardt, T. (2014). Beta-lactam antibiotics induce a lethal 
malfunctioning of the bacterial cell wall synthesis machinery. Cell, 159(6), 1300-1311. 
doi:10.1016/j.cell.2014.11.017 
2. Bush, K., & Fisher, J. F. (2011). Epidemiological expansion, structural studies, and clinical 
challenges of new -lactamases from Gram-negative bacteria. Annual Review of 
Microbiology, 65(1), 455-478. doi:10.1146/annurev-micro-090110-102911 
3. Bush, K., & Jacoby, G. A. (2009). Updated functional classification of -lactamases. 
Antimicrobial Agents and Chemotherapy, 54(3), 969-976. doi:10.1128/aac.01009-09 
4. Palzkill, T. (2012). Metallo--lactamase structure and function. Annals of the New York 
Academy of Sciences, 1277(1), 91-104. doi:10.1111/j.1749-6632.2012.06796.x 
5. Nordmann, P., Dortet, L., & Poirel, L. (2012). Carbapenem resistance in 
Enterobacteriaceae: Here is the storm! Trends in Molecular Medicine, 18(5), 263-272. 
doi:10.1016/j.molmed.2012.03.003 
6. Trecarichi, E. M., & Tumbarello, M. (2017). Therapeutic options for carbapenem-resistant 
Enterobacteriaceae infections. Virulence, 8(4), 470-484. 
doi:10.1080/21505594.2017.1292196 
7. Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011). 
Carbapenems: Past, present, and future. Antimicrobial Agents and Chemotherapy, 55(11), 
4943–4960. doi:10.1128/AAC.00296-11 
8. Van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013). Carbapenem-resistant 
Enterobacteriaceae: a review of treatment and outcomes. Diagnostic Microbiology and 
Infectious Disease, 75(2), 115-120. doi:10.1016/j.diagmicrobio.2012.11.009 
9. Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015). Treatment options for 
carbapenem-resistant Enterobacteriaceae infections. Open Forum Infectious Diseases, 
2(2), ofv050-ofv050. doi:10.1093/ofid/ofv050 
10. Lutgring, J. D., & Limbago, B. M. (2016). The problem of carbapenemase-producing-
carbapenem-resistant-Enterobacteriaceae detection. Journal of Clinical Microbiology, 
54(3), 529-534. doi:10.1128/jcm.02771-15 
11. Meletis, G. (2015). Carbapenem resistance: Overview of the problem and future 
perspectives. Therapeutic Advances in Infectious Disease, 3(1), 15-21. 
doi:10.1177/2049936115621709 
12. Ho, P. L., Cheung, Y. Y., Wang, Y., Lo, W. U., Lai, E. L., Chow, K. H., & Cheng, V. C. 
(2016). Characterization of carbapenem-resistant Escherichia coli and Klebsiella 
pneumoniae from a healthcare region in Hong Kong. European Journal of Clinical 
Microbiology & Infectious Diseases, 35(3), 379-385. doi:10.1007/s10096-015-2550-3 
13. Drawz, S. M., & Bonomo, R. A. (2010). Three decades of -lactamase inhibitors. Clinical 
Microbiology Reviews, 23(1), 160-201. doi:10.1128/cmr.00037-09 
14. Queenan, A. M., & Bush, K. (2007). Carbapenemases: The versatile -lactamases. Clinical 
Microbiology Reviews, 20(3), 440-458. doi:10.1128/cmr.00001-07 
 140 
 
15. Watkins, R. R., Papp-Wallace, K. M., Drawz, S. M., & Bonomo, R. A. (2013). Novel -
lactamase inhibitors: A therapeutic hope against the scourge of multidrug resistance. 
Frontiers in Microbiology, 4. doi:10.3389/fmicb.2013.00392 
16. Hecker, S. J., Reddy, K. R., Totrov, M., Hirst, G. C., Lomovskaya, O., Griffith, D. C., … 
Dudley, M. N. (2015). Discovery of a cyclic boronic acid -lactamase inhibitor (RPX7009) 
with utility vs class A serine carbapenemases. Journal of Medicinal Chemistry, 58(9), 
3682-3692. doi:10.1021/acs.jmedchem.5b00127 
17. Abboud, M. I., Damblon, C., Brem, J., Smargiasso, N., Mercuri, P., Gilbert, B., Frère, J. 
(2016). Interaction of avibactam with class B metallo--lactamases. Antimicrobial Agents 
and Chemotherapy, 60(10), 5655-5662. doi:10.1128/aac.00897-16 
18. Castanheira, M., Rhomberg, P. R., Flamm, R. K., & Jones, R. N. (2016). Effect of the -
lactamase inhibitor vaborbactam combined with meropenem against serine 
carbapenemase-producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 
60(9), 5454-5458. doi:10.1128/aac.00711-16 
19. King, A. M., Reid-Yu, S. A., Wang, W., King, D. T., De Pascale, G., Strynadka, N. C., 
Wright, G. D. (2014). Aspergillomarasmine A overcomes metallo--lactamase antibiotic 
resistance. Nature, 510(7506), 503-506. doi:10.1038/nature13445 
20. Koteva, K., King, A. M., Capretta, A., & Wright, G. D. (2015). Total synthesis and activity 
of the metallo--lactamase inhibitor Aspergillomarasmine A. Angewandte Chemie, 
128(6), 2250-2252. doi:10.1002/ange.201510057 
21. Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2013). New -lactamase inhibitors: 
A therapeutic renaissance in an MDR world. Antimicrobial Agents and Chemotherapy, 
58(4), 1835-1846. doi:10.1128/aac.00826-13 
22. Brem, J., Cain, R., Cahill, S., McDonough, M. A., Clifton, I. J., Jiménez-Castellanos, J., 
Schofield, C. J. (2016). Structural basis of metallo--lactamase, serine--lactamase and 
penicillin-binding protein inhibition by cyclic boronates. Nature Communications, 7, 
12406. doi:10.1038/ncomms12406 
23. Silver, L. L. (2011). Challenges of Antibacterial Discovery. Clinical Microbiology 
Reviews, 24(1), 71-109. doi:10.1128/cmr.00030-10 
24. Brown, E. D., & Wright, G. D. (2016). Antibacterial drug discovery in the resistance era. 
Nature, 529(7586), 336-343. doi:10.1038/nature17042 
25. Murray, C. W., & Rees, D. C. (2009). The rise of fragment-based drug discovery. Nature 
Chemistry, 1(3), 187-92. doi:10.1038/nchem.217 
26. Erlanson, D. A. (2011). Introduction to fragment-based drug discovery. Topics in Current 
Chemistry, 1-32. doi:10.1007/128_2011_180 
27. Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012). Fragment-based approaches 
in drug discovery and chemical biology. Biochemistry, 51(25), 4990-5003. 
doi:10.1021/bi3005126 
28. Wong, D., & Van Duin, D. (2017). Novel beta-lactamase inhibitors: Unlocking their 
potential in therapy. Drugs, 77(6), 615-628. doi:10.1007/s40265-017-0725-1 
29. Page, M. I., & Badarau, A. (2008). The mechanisms of catalysis by metallo--lactamases. 
Bioinorganic Chemistry and Applications, 2008, 1-14. doi:10.1155/2008/576297 
 141 
 
30. Pemberton, O. A., Zhang, X., & Chen, Y. (2017). Molecular basis of substrate recognition 
and product release by the Klebsiella pneumoniae carbapenemase (KPC-2). Journal of 
Medicinal Chemistry, 60(8), 3525-3530. doi:10.1021/acs.jmedchem.7b00158 
31. Zhang, H., & Hao, Q. (2011). Crystal structure of NDM-1 reveals a common -lactam 
hydrolysis mechanism. The FASEB Journal, 25(8), 2574-2582. doi:10.1096/fj.11-184036 
32. King, D. T., Worrall, L. J., Gruninger, R., & Strynadka, N. C. (2012). New Delhi metallo-
-lactamase: Structural insights into -lactam recognition and inhibition. Journal of the 
American Chemical Society, 134(28), 11362-11365. doi:10.1021/ja303579d 
33. Papp-Wallace, K. M., Taracila, M., Wallace, C. J., Hujer, K. M., Bethel, C. R., Hornick, J. 
M., & Bonomo, R. A. (2010). Elucidating the role of Trp105 in the KPC-2 -lactamase. 
Protein Science, 19(9), 1714-1727. doi:10.1002/pro.454 
34. Bethel, C. R., Taracila, M., Shyr, T., Thomson, J. M., Distler, A. M., Hujer, K. M., … 
Bonomo, R. A. (2011). Exploring the inhibition of CTX-M-9 by -lactamase inhibitors 
and carbapenems. Antimicrobial Agents and Chemotherapy, 55(7), 3465-3475. 
doi:10.1128/aac.00089-11 
35. Tomanicek, S. J., Standaert, R. F., Weiss, K. L., Ostermann, A., Schrader, T. E., Ng, J. D., 
& Coates, L. (2012). Neutron and x-ray crystal structures of a perdeuterated enzyme 
inhibitor complex reveal the catalytic proton network of the Toho-1 -lactamase for the 
acylation reaction. Journal of Biological Chemistry, 288(7), 4715-4722. 
doi:10.1074/jbc.m112.436238 
36. Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & 
Docquier, J. (2013). Structural insight into potent broad-spectrum inhibition with 
reversible recyclization mechanism: Avibactam in complex with CTX-M-15 and 
Pseudomonas aeruginosa AmpC -lactamases. Antimicrobial Agents and Chemotherapy, 
57(6), 2496-2505. doi:10.1128/aac.02247-12 
37. Sun, J., Deng, Z., & Yan, A. (2014). Bacterial multidrug efflux pumps: Mechanisms, 
physiology and pharmacological exploitations. Biochemical and Biophysical Research 
Communications, 453(2), 254-267. doi:10.1016/j.bbrc.2014.05.090 
38. Borges-Walmsley, M. I., McKeegan, K. S., & Walmsley, A. R. (2003). Structure and 
function of efflux pumps that confer resistance to drugs. Biochemical Journal, 376(2), 313–
338. doi:10.1042/BJ20020957 
39. Chen, Y., & Shoichet, B. K. (2009). Molecular docking and ligand specificity in fragment-
based inhibitor discovery. Nature Chemical Biology, 5(5), 358-364. 
doi:10.1038/nchembio.155 
40. Johnson, J. W., Gretes, M., Goodfellow, V. J., Marrone, L., Heynen, M. L., Strynadka, N. 
C., & Dmitrienko, G. I. (2010). Cyclobutanone analogues of -lactams revisited: Insights 
into conformational requirements for inhibition of serine- and metallo--lactamases. 
Journal of the American Chemical Society, 132(8), 2558-2560. doi:10.1021/ja9086374 
41. Cahill, S. T., Cain, R., Wang, D. Y., Lohans, C. T., Wareham, D. W., Oswin, H. P., Brem, 
J. (2017). Cyclic boronates inhibit all classes of -lactamases. Antimicrobial Agents and 
Chemotherapy, 61(4), e02260-16. doi:10.1128/aac.02260-16 
 142 
 
42. Lorber, D. M., & Shoichet, B. K. (2005). Hierarchical Docking of Databases of Multiple 
Ligand Conformations. Current Topics in Medicinal Chemistry, 5(8), 739–749. 
43. Irwin, J. J., & Shoichet, B. K. (2005). ZINC – A free database of commercially available 
compounds for virtual screening. Journal of Chemical Information and Modeling, 45(1), 
177–182. doi:10.1021/ci049714 
44. Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. (2011). 
iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. 
Acta Crystallographica Section D Biological Crystallography, 67(4), 271-281. 
doi:10.1107/s0907444910048675 
45. Evans, P. (2006). Scaling and assessment of data quality. Acta Crystallographica Section 
D Biological Crystallography, 62(1), 72-82. doi:10.1107/S0907444905036693 
46. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., 
Wilson, K. S. (2011). Overview of the CCP4 suite and current developments. Acta 
Crystallographica Section D: Biological Crystallography, 67(4), 235–242. 
doi:10.1107/S0907444910045749 
47. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & 
Read, R. J. (2007). Phaser crystallographic software. Journal of Applied Crystallography, 
40(4), 658–674. doi:10.1107/S0021889807021206 
48. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Zwart, 
P. H. (2010). PHENIX: A comprehensive Python-based system for macromolecular 
structure solution. Acta Crystallographica Section D Biological Crystallography, 66(2), 
213-221. doi:10.1107/s0907444909052925 
49. Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., 
Mustyakimov, M., Adams, P. D. (2012). Towards automated crystallographic structure 
refinement with phenix.refine . Acta Crystallographica Section D: Biological 
Crystallography, 68(4), 352–367. doi:10.1107/S0907444912001308 
50. Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010). Features and development 
of Coot. Acta Crystallographica Section D: Biological Crystallography, 66(4), 486–501. 
doi:10.1107/S0907444910007493 
51. Moriarty, N. W., Grosse-Kunstleve, R. W., & Adams, P. D. (2009). electronic Ligand 
Builder and Optimization Workbench (eLBOW): A tool for ligand coordinate and restraint 
generation. Acta Crystallographica Section D: Biological Crystallography, 65(Pt 10), 
1074–1080. doi:10.1107/S0907444909029436 
52. Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., 
Richardson, D. C. (2007). MolProbity: All-atom contacts and structure validation for 
proteins and nucleic acids. Nucleic Acids Research, 35(Web Server), W375-W383. 
doi:10.1093/nar/gkm216 
53. DeLano W.L. (2002). The PyMOL user’s manual. DeLano Scientific, San Carlos, CA. pp 
452. 
 
  
 143 
 
 
 
 
 
 
 
Chapter 6:  
Summary 
 
 Production of -lactamase enzymes by Gram-negative pathogens is a major cause of 
bacterial resistance against the commonly used -lactam antibiotics. -Lactam resistance mediated 
by -lactamases can be overcome through the use of BLIs. Clavulanic acid, sulbactam, and 
tazobactam are examples of clinically used BLIs that demonstrate activity against class A and D 
-lactamases. Unfortunately, because these inhibitors possess a -lactam ring, they are susceptible 
to degradation by -lactamases such as KPC-2 (class A serine enzyme) and NDM-1/VIM-2 (class 
B metalloenzymes). As a result, a better understanding of the catalytic mechanism of -lactamases 
is crucial in discovering novel inhibitors active against both serine and metalloenzymes.  
 The first project addressed the cephalosporinase and carbapenemase activity of the serine 
carbapenemase KPC-2. Three crystal structures: apo, hydrolyzed cefotaxime, and hydrolyzed 
faropenem, provided experimental insights into the substrate recognition of KPC-2 and how 
alternative conformations of Ser70 and Lys73 promote expulsion of the hydrolyzed product from 
the active site. The ability of KPC-2 to bind such a wide variety of -lactam substrates can be 
exploited through rational drug design to engineer high affinity inhibitors. 
 The second project focused on understanding the proton transfer process involved in the 
mechanism of avibactam inhibition against serine -lactamases. Ultrahigh resolution X-ray 
crystallography of CTX-M-14 bound with avibactam allowed for elucidation of protonation states 
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of the key catalytic residues, Lys73, Ser130, and Glu166. Avibactam impedes a critical proton 
transfer between Glu166 and Lys73, keeping these residues as neutral species, and thereby leaving 
a stable EI complex resistant to hydrolysis. 
 The third project investigated the influence of binding kinetics on vaborbactam inhibition 
of KPC-2. The binding kinetic experiments revealed that vaborbactam has an extremely slow off-
rate with KPC-2 leading to a residence time of close to 1,000 min, which is much greater than the 
bacterial generation time (~ 20 min). The long residence time of vaborbactam translated to 
favorable in vitro and in vivo efficacy. A high-resolution crystal structure of vaborbactam bound 
to KPC-2 demonstrated the covalent bond with the catalytic serine as well as the extensive non-
covalent interactions that contribute to binding affinity. 
 The final project focused on discovering inhibitors that could simultaneously target serine 
-lactamases and MBLs. Using molecular docking and FBDD, a series of phosphonate-based 
compounds were identified that displayed micromolar potency against KPC-2, NDM-1, and VIM-
2. Crystal structures of these inhibitors with KPC-2, NDM-1, and VIM-2 demonstrated their 
interactions with conserved active site features. The phosphonate-based inhibitors reduced the 
MIC of imipenem against a K. pneumoniae strain expressing KPC-2 and an E. coli strain 
expressing NDM-1. Ultimately, these phosphonate-based compounds will serve as scaffolds for 
the development of potent inhibitors targeting serine -lactamases and MBLs. 
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Appendix 2: 
 
Chapter 4 Supplementary Data 
 
 
 
Figure S4.1. Lineweaver-Burk plot of KPC-2 inhibition by vaborbactam. 
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Figure S4.2. KPC-2 inactivation profile using boronic acid BLIs. 
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Figure S4.3. Time-dependence of vaborbactam inhibition of KPC-2. 
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Figure S4.4. Vaborbactam and tazobactam kinetic behavior with KPC-2. 
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Figure S4.5. Jump dilution can reverse vaborbactam inhibition of KPC-2. 
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Table S4.1. MIC of various -lactams against P. aeruginosa expressing KPC-2 and KPC-2 S130G 
 
 
  
Plasmid Ceftazidime Cefepime Carbenicillin Piperacillin Meropenem Aztreonam 
vector 2 0.125 0.5 0.25 0.125 1 
KPC-2 32 128 >512 128 128 16 
KPC-2 S130G 1 0.125 128 64 0.25 0.25 
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Table S4.2. X-ray data collection and refinement statistics 
Structure KPC-2 with vaborbactam 
Data Collection  
  
Space group P22121 
Cell dimensions  
a, b, c (Å) 55.77, 59.97, 77.72 
(°) 90, 90, 90 
Resolution (Å) 47.48 -1.25 (1.295-1.25) 
No. of unique reflections 72,556 (7159) 
Rmerge (%) 9.0 (91.2) 
I/σ(I) 8.9 (1.8) 
Completeness (%) 99.7 (99.7) 
Multiplicity 5.8 (5.8)  
 
Refinement  
 
 
Resolution (Å) 47.48 -1.25 
Rwork (%) 14.7 (26.9) 
Rfree (%) 17.0 (28.6) 
No. atoms  
     Protein 2160 
     Ligand/Ion 66 
     Water   305 
B-factors (Å2)  
     protein 14.98 
     ligand/ion 28.65 
     water 35.29 
RMS deviations  
     Bond lengths (Å) 0.007 
     Bond angles (°) 1.07 
Ramachandran plot  
      favored (%) 98.88 
      allowed (%) 1.12 
      outliers (%) 0 
 PDB code 5WLA 
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Figure S5.1. KPC-2 bound to (A) compound 2 and (B) compound 3. Compounds are colored in green and the 
unbiased Fo-Fc map is colored in gray and contoured at 2 . 
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Figure S5.2. NDM-1 bound to (A) compound 2, (B) compound 3, (C) compound 7, (D) compound 11, and (E) 
compound 12. Compounds are colored in green and the unbiased Fo-Fc map is colored in gray and contoured at 2 . 
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Figure S5.2. Continued. 
